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Chronic diseases have been recognised as a major health issue, and 
their chronic nature along with their complications result in a significant 
economic burden. Because of the increasing prevalence of these 
diseases, a better understanding of the cost-of-illness (COI) related to 
them is important. In Singapore, little is known about the costs of 
chronic conditions and their associated factors. In this thesis study, the 
costs of three common chronic conditions were estimated: (i) diabetes 
mellitus (DM), (ii) strokes and (iii) osteoporotic fractures. 
First, a systematic review was conducted of MEDLINE and Scopus 
journal articles published in English from 2007 to 2011 that reported
the cost of type 1 and/or 2 DM. The systematic search yielded 30 
articles, which varied considerably in their study design, perspective 
and included cost categories. It was found that inpatient costs was the 
major contributor to direct cost in half of the studies that include 
inpatient costs, physician services and medications.
Second, direct medical costs associated with type 2 diabetes mellitus
(T2DM) was estimated and the relationship between both demographic 
and clinical state variables and the total estimated expenditure were
examined. Of the total healthcare expenditure, the main cost driver was 
inpatient costs. Accident and emergency (A&E) services were only a 
small proportion of the total costs, while the major source of cost for 
viii
outpatient services was physician visits. DM interventions such as the 
use of insulin only and the combination of both oral medications and 
insulin as well as having cerebrovascular, cardiovascular, peripheral 
vascular disease and nephropathy complications were found to be 
independent determinants of total costs.
Third, the direct medical cost associated with stroke was estimated,
and the relationship between the total calculated costs and individual 
demographic characteristics, type of stroke, length of post-stroke 
period, complications and comorbidities were examined. Inpatient costs 
accounted for the majority of the total estimated healthcare expenditure, 
followed by outpatient services and A&E services. Healthcare 
expenditure across all services was substantially higher in acute 
patients than prevalent patients. Independent determinants of greater 
total costs were stroke types such as ischaemic stroke (IS), 
subarachnoid haemorrhage (SAH) and intracerebral haemorrhage 
(ICH), shorter post-stroke period, having more than one complication 
and a greater number of comorbidities. 
Fourth, a prospective study was conducted to estimate the total direct 
and indirect costs of osteoporotic fractures in Singapore. Taking both 
the hospital’s and patient’s perspective, the main cost contributor in the 
direct medical cost was inpatient costs, while the major source of cost
for outpatient services was rehabilitation services. Informal care 
accounted for the majority of the total estimated expenditure for indirect 
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costs, and this amount was substantially higher in patients with acute 
fracture. Overall, direct costs were significantly higher than indirect 
costs for both acute and prevalent patients. 
In conclusion, this thesis provided important information on the 
economic burden of major chronic conditions in Singapore’s population. 
The findings of this project have paved the way for future 
pharmacoeconomic evaluations, which are expected to contribute to 
the development of healthcare policies, appropriate health resource
allocation and justification of intervention programs.
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Chapter 1 Introduction
1.1 Cost-of-Illness Studies – Determining the Total Financial Burden of 
a Disease
1.1.1 Overview
Cost-of-illness studies summarise the resources used and lost as a 
result of a particular disease, making possible an analysis of the 
medical and economic burden that a disease may have on society as a 
whole, the health service and/or the patient [1-3]. It should be noted 
that COI studies serve a different purpose than health economic 
evaluations such as cost benefit analysis, cost effectiveness analysis, 
or cost utility analysis, which focus on the assessment of the cost of 
interventions rather than estimating the cost of a particular disease [2]. 
The framework for present COI studies stems from the work of Fein [4],  
Mushkin and Collings [5], Weibrod [6], Rice and Cooper [7]  and others 
during the 1950’s and 1960’s. In particular, in 1966, Dorothy Rice 
published a monograph that proposed a method of estimating costs 
from available information in existing data sets. This monograph
established what has now become the standard for all COI studies: 
addressing the economic COI in the two categories of direct costs and 
indirect costs. The term 'cost' in health economics refers to the value of 
the outcome of using a particular good or service, rather than its price.
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A third category, the psychosocial cost of illness or its impact on quality 
of life, is often mentioned in the literature but seldom measured in COI 
studies due to the complexity of such cost measurement [8-12]. COI 
studies can estimate the maximum amount that could potentially be 
saved or gained if a disease were to be eradicated [13]. However, 
arriving at this figure, or even estimating the economic burden of a 
disease, is a challenging task due to the fact that important data are
not always available.
1.1.2 Significance of COI Studies
COI studies translate the burden of a disease into fiscal monetary 
value. With both direct and indirect costs considered at a micro- and 
macroeconomic level, this information is used to: (1) quantify the 
magnitude of the disease in dollar terms; (2) justify intervention 
programs; (3) develop policies and initiatives to allocate resources 
appropriately; (4) assist in the allocation of research monies on specific 
diseases and (5) provide an economic framework for program valuation
[14]. Cost estimates provide valuable information to policy makers, 
healthcare providers, third-party payers, patients and others interested 
in understanding how their healthcare dollars are being spent [15]. 
Knowledge of the costs of an illness can help policy makers decide 
which diseases need to be addressed first by healthcare and 
prevention policies. Additionally, these studies can indicate for which 
diseases cures would be especially valuable in reducing the burden of 
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disease. For specific stakeholders, such as the government, COI 
studies can show the financial impact a disease has on public 
programs such as government subsidies or programs [13]. For 
employers, these studies can show which diseases have a particularly 
large effect on their costs [16, 17]. Moreover, COI studies provide a 
framework for the costs estimation in cost-effectiveness and cost-
benefit analyses [14, 18]. Therefore, COI studies are a valuable tool for 
advocating that attention and resources be directed towards a specific 
disease.
1.1.3 Types of Costs
In a COI, three cost components that can be estimated are: (1) direct 
(medical and non-medical) costs; (2) indirect costs; and (3) intangible 
costs. These components are presented in Figure 1.1 as a conceptual 
framework of the economic burden of diabetes. This framework was an 
adaptation of a broader framework developed by Kirigia et al [19].
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1.1.3.1 Direct Costs
The direct cost of a disease is derived from the opportunity cost used 
for the treatment of the disease. Opportunity cost, in the context of COI 
studies, is the value of all the resources that could have been 
otherwise allocated but were instead used or lost due to a disease [11]. 
The fiscal resources that make up the opportunity cost are either direct 
medical costs or direct non-medical costs.
Direct medical costs are the easiest to calculate and may include costs 
from hospital inpatient care, physician inpatient care, physician 
outpatient care, emergency department visits, nursing home care, 
hospice care, rehabilitation care, specialists' and other health 
professionals' care, diagnostic tests, prescription drugs and drug 
sundries, as well as other medical supplies, all of which tend to have 
receipts of transactions maintained by hospitals, third-party payers, 
and/or patients [11, 13].
Direct non-medical costs are defined as expenses paid by the patient 
and his or her family that are directly associated with a disease, but are 
not medical in nature, for example, transportation, relocation expenses 
and informal care. Due to their indirect nature, such expenses are 
easily overlooked but they are a crucial contributor to direct cost 
estimates [13, 20, 21].
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1.1.3.2 Indirect Costs
Indirect costs tend to account for a large proportion of the total 
estimated cost in COI studies, although several issues exist in the 
estimation of indirect costs. Indirect costs may incorporate productivity 
losses due to a disease's morbidity and mortality. Such productivity 
losses may be of a labour or non-labour nature and, in a manner 
similar to direct costs, such values represent an opportunity cost. Other 
indirect costs that may be considered are related to employment costs
[13, 21]. Absenteeism is a traditional representation of the loss of 
productivity that occurs when the workforce population is unable to 
work as a direct or indirect result of a disease. Typically, work 
absences reflect a forgone productivity. Meanwhile, decreased 
productivity due to presenteeism is becoming a recognised 
measurement of employment cost. Presenteeism contributes to indirect 
costs because even though a member of the workforce may be present 
at work, their performance and overall productivity may be negatively 
affected as a result of the disease [22]. Therefore, indirect cost can 
account for a substantial proportion of total costs in COI studies.
1.1.3.3 Intangible Costs
Intangible costs typically take the form of quality of life measures, 
which may include a patient's psychological pain, discomfort, anxiety 
and distress associated with a disease [23]. As these costs are difficult 
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to quantify in monetary terms, intangible costs are often excluded from 
the estimation in COI studies [21].
1.1.4 Perspective
In addition to different types of costs, another important consideration 
in COI studies is the perspective taken. Depending on the perspective 
chosen, an estimation of costs will vary. For example, an end-user, 
such as the patient, may only consider their out-of-pocket costs, 
whereas an employer may only consider loss of productivity and 
worker's compensation insurance premiums and/or pay-outs. While 
both are valid perspectives, they are also narrow and underestimate 
the total economic burden of a disease, which includes direct, indirect 
and intangible costs. The most comprehensive way for calculating total 
costs in COI studies is by taking on a societal perspective [13, 20]. 
Quantifying COI estimates financed by specific payers provides an 
additional level of detail that can be used to identify the distribution of 
resource utilisation and costs across healthcare sectors (i.e. private vs 
public expenditures) and populations (i.e. gender and age-specific 
costs) and can assist in an analysis of whether healthcare resources 
are being equitably distributed [15].
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1.1.5 Discounting
Discounting is an economic technique that is based on time preference. 
It is often explained as an opportunity cost of interest. Discounting 
calculates the present value of inputs and benefits that will accrue in 
the future. For example, any income earned today may produce 
interest through investment.
With regards to COI studies, discounting is only applicable for direct 
costs and indirect costs that accrue over multiple years. In the literature, 
discounting figures ranging from 0 to 10 percent have been used. 
However, in most COI studies, a rate of 3 percent is often selected [13].
1.1.6 Approaches for Cost Estimation
1.1.6.1 Incidence-Based, Prevalence-Based and Present Cost Method
There are three common methods of determining COI estimates. An 
incidence-based approach examines costs from a cohort of patients, 
usually from diagnosis until death (lifetime costs) [3, 24]. Incidence-
based methods are labour-intensive and require knowledge of the 
disease course, survival rates, and the impact of the disease on 
lifetime income. Such an approach is most applicable when making 
decisions between alternative treatments and studying short-term cost-
effectiveness and acute diseases.
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A prevalence-based approach differs in that, instead of a lifetime, the 
cost of a disease is examined in a specific time frame. It is the most 
commonly used method of estimating the total COI. A prevalence-
based method yields findings that can be directly correlated to fiscal
impact, cost control and chronic diseases analysis [25].
The third approach is the present cost method. It shares similarities 
with the prevalence-based approach, but it is unique in that it looks 
retrospectively in order to estimate losses in productivity. In essence, 
this method considers mortality losses attributed to individuals who 
would otherwise have had been alive during a specific time frame. 
Therefore the opportunity cost is reflected in deaths associated with a 
particular disease [26].
1.1.6.2 Approach for Direct Costs Estimation 
There are two primary approaches to estimating direct costs: the top-
down approach and the bottom-up approach. The top-down approach 
examines costs in an aggregate form for specific diseases. It estimates 
economic costs by using aggregate data on mortality, morbidity, 
hospital admissions, general physician visits, disease-related costs and 
other health-related indicators, which can be identified by primary
and/or secondary International Classification of Disease (ICD) codes
[27, 28]. For example, in order to derive the cost estimate of 
medications for the average patient with DM, annual hospital 
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expenditure on DM-related medications are divided by the number of 
patients with DM [29, 30].
In the bottom-up approach, also known as micro-costing, it starts with 
the consumption of resources at the patient’s level, using costs of 
individual units of services performed. For example, in order to derive 
the cost estimate of medications for individual patients, the number of 
medications prescribed will be multiplied by unit prices [28, 30].
In recent years, several COI studies have used estimates from the 
literature to project direct cost. In this approach, previous estimates are 
adjusted to account for changes over time in prevalence, healthcare 
use and mortality related to the disease, as well as inflation. 
1.1.6.3 Approach for Indirect Costs Estimation 
Indirect costs may be derived in three ways: the human capital 
approach, the friction cost approach, and the willingness-to-pay 
approach. The human capital approach is the most commonly used 
method. It considers the foregone income of the patient and their 
caregivers and takes into account premature mortality or permanent 
disability, which often includes the value of household work [13, 20]. 
On the other hand, the friction cost method measures only the 
production losses during the time it takes to replace a worker [31, 32].
Lastly the willingness-to-pay approach uses various methods such as 
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surveys or questionnaires to determine the amount an individual would 
pay to reduce the probability of illness or mortality [13]. 
1.2 Chronic Conditions – A Major Cause of Mortality and Economic 
Burden
Chronic diseases are long-lasting medical conditions that are generally 
progressive. In short, they can be controlled but not cured. They are 
also the major cause of premature adult deaths in many parts of the 
world, representing 63.0% of all annual deaths, with most occurring in 
low- and middle-income countries [33]. According to the World Health 
Organization (WHO), almost half of all chronic disease deaths occur in 
people under the age of 70 [33]. The prevalence of chronic conditions 
continues to increase, and by 2020, an estimated 157 million 
Americans (nearly 50.0% of the population) are projected to have at 
least one chronic condition [34]. 
The three chronic conditions studied in this project are DM, stroke, and 
osteoporosis-related fractures. Globally, the total number of people 
with DM is projected to rise from 171 million in 2000 to 366 million in
2030 [35]. Furthermore, approximately 16 million first-occurrence 
strokes occur around the world per year, accounting for 5.7 million 
deaths [36]. In 2002, stroke-related disability was judged to be the sixth 
most common cause of reduced disability-adjusted life-years (DALYs) 
[37]. As for the third condition studied, in 2000, 9 million osteoporosis-
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related fractures occurred worldwide, including 1.6 million hip fractures, 
1.7 million forearm fractures and 1.4 million clinical vertebral fractures 
[38, 39]. Therefore, it is not surprising that considerable attention has 
been directed toward designing treatment protocols to prevent or inhibit 
the progression of these three specific chronic conditions.
In Singapore, the prevalence of DM has risen to 12.3% in 2013, from 
8.2% in 2004 and 9.0% in 1998 [40, 41]. Furthermore, stroke is the 
fourth leading cause of death in Singapore, accounting for 9.0% of total 
deaths, with a prevalence of 3.7% and an incidence of 1.8/1,000 
person-years [42, 43]. Also significant are osteoporosis-related hip 
fractures, with incidence rates that have risen 1.5-fold for men and 5-
fold for women since the 1960s. The age-adjusted hip fractures rates 
among women over the age of 50 years are about 402/100,000 
females. Moreover, in 2006, the government introduced the Chronic 
Disease Management Programme (CDMP) with the aim of providing 
financial assistance (Medisave) for patients with DM, hypertension, 
hyperlipidaemia and stroke. It was later expanded to include asthma 
and chronic obstructive pulmonary disease (COPD), and by 2014, 
schizophrenia, bipolar disorder, dementia, osteoarthritis, benign 
prostatic hyperplasia, anxiety, Parkinson’s disease and 
nephrosis/nephritis were also added to the list, giving a total of 15 
chronic diseases under the CDMP [44]. This cumulative list serves as a 
reminder of the growing epidemic currently faced by the Singapore 
population. 
Chapter 1. Introduction                                                                                        Ng, CS
14
1.3 COI Studies in Patients with DM, Stroke and Osteoporotic 
Fractures – Top-Ranked Disease Burden with an Increasing Incidence 
in Asia
The incidence of diabetes, stroke and osteoporosis, three major 
causes of morbidity and mortality, are increasing rapidly among the 
Asian population [45-50]. The chronic nature of these conditions along 
with their complications makes them very costly diseases. 
In the United States (U.S.), 84.0% of the total healthcare expenditure in 
2006 was for individuals who had one or more chronic conditions [51]. 
Four of the five most expensive health conditions are chronic 
conditions [52]. A study conducted in 2007, reported that seven chronic 
diseases (cancer, diabetes, hypertension, stroke, heart disease, 
pulmonary conditions, mental illness) have a total impact on the 
economy of US$1.3 trillion annually. By the year 2023, this number is 
projected to increase to US$4.2 trillion dollars [53].
The direct costs of DM consume from 2.5% to 15.0% of annual 
healthcare budgets, depending on local prevalence and available 
treatments [54]. In 2012, the total estimated cost of diagnosed diabetes 
in the U.S. was estimated to be US$245.0 billion, including US$176.0 
billion in direct medical costs and US$69.0 billion in decreased 
productivity [55]. Worldwide, stroke consumes about 2–4% of total 
healthcare expenditure, and in developed countries stroke accounts for 
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more than 4% of direct healthcare costs [56]. The total annual costs of 
stroke have been variously estimated at US$40 billion in the U.S. [57], 
AUS$1.3 billion in Australia [58], and £8.9 billion in the United Kingdom
[59]. On the other hand, osteoporosis-related fractures was estimated 
to be US$20 billion in the U.S. [60], €30 billion in the European Union
[61] and AU$1.8 billion in Australia [62]. 
With an aging population, Singapore is likely to see a marked increase 
in individuals with complex and chronic diseases, in particular, DM, 
stroke and osteoporosis. 
1.4 Research Significance
In spite of a rising prevalence of chronic conditions in Singapore, the 
costs of these diseases have not been well examined. Understanding 
the economic burden of these conditions could enhance better 
resource allocation and also help develop and improve intervention 
programs intended to prevent these conditions and complications. 
The significance of the first study is to provide a framework for 
appropriate allocation of healthcare resources and assist government 
and healthcare practitioners to gain a better understanding of the 
trends in DM costs. In addition, with the utilisation of the National 
Healthcare Group (NHG) Chronic Disease Management System 
(CDMS), the second and third studies’ results may be generalized to
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the local population. These findings could also serve as an aid for cost 
management in the treatment of DM and stroke. Finally, the fourth
study was one of the few studies that examined both the direct and 
indirect costs of osteoporotic fractures, which findings may help
policymakers and healthcare organisations to assess the impact of 
interventions on the costs of osteoporosis-related fractures.
1.5 Research Objectives
The main objective of the present thesis is to estimate the total 
economic burden of DM, stroke and osteoporosis-related fractures in 
Singapore. This thesis can be broadly separated into two main sections 
with their specific objectives. 
First, the merits of COI studies have been well established in earlier 
studies [13-15]. Not only are they a valuable tool in establishing the 
total economic burden of a disease, but they are also an important 
component for pharmacoeconomic evaluations. However, due to the 
variability in epidemiologic and economic data availability depending 
upon the disease in question, making direct comparisons of COI 
estimates across different populations may be misleading [15].
Therefore, the second chapter aims to:
 Describe the methods used in published DM COI studies.
 Summarise the findings reported in the identified studies regarding 
the economic impact of DM.
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 Identify the strengths and limitations of the various methods utilised.
 Examine how the different methods applied influence reported cost 
estimates.
Second, Singapore consists of 3 major ethnic groups, namely, the 
Chinese (74.0%), Malays (13.0%) and Indians (9.1%) [63]. These 
groups have a high prevalence and incidence of individuals with DM, 
stroke and osteoporosis-related fractures. In 2005, diabetes was most 
prevalent among Indians (20.4%), compared to Malays (17.1%) and 
the Chinese (8.2%) [64]. Chinese and Indian people had similar age-
standardised incidence rates of stroke while Malays had the highest 
from 2009 to 2013 [65]. Age-adjusted hip fracture rates were higher in 
the Chinese than those in Indians and Malays [47]. Despite the high 
prevalence and impact of these diseases, their economic impact has
not been well studied. Therefore, the third, fourth and fifth chapters aim
to:
 Estimate the total direct medical costs associated with T2DM in 
Singapore and to examine the relationship between demographic 
and clinical state variables with the total estimated expenditure.
 Estimate the total direct medical costs associated with stroke in 
Singapore and to examine the relationship between both 
demographic variables and clinical state variables and the total 
estimated expenditure.
 Estimate the total direct and indirect costs associated with 
osteoporotic fractures in Singapore.
18
CHAPTER TWO
Cost-of-Illness Studies of Diabetes Mellitus: 
A Systematic Review
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Chapter 2 Cost-of-Illness Studies of Diabetes Mellitus: A 
Systematic Review
Introduction 
Diabetes mellitus is a leading cause of mortality worldwide [66], 
accounting for approximately 4.6 million deaths in 2011 [67]. There are 
an estimated 382 million people living with DM in 2013 and this number 
is expected to increase to 592 million by 2035 [68]. This global 
increase in DM is attributed to population growth and aging and an 
increasing trend towards unhealthy diets, sedentary lifestyles and 
obesity [35]. Individuals with DM often develop macrovascular 
(cardiovascular, cerebrovascular and peripheral vascular diseases) 
and microvascular (retinopathy, nephropathy and neuropathy) diseases 
[69, 70]. These chronic complications are highly prevalent in patients 
with T2DM, with 4 in 10 developing one or more of the complications
[71, 72].
The chronic nature of DM and its many complications make it a costly 
disease [3]. In 2010, the estimated worldwide cost to treat and prevent 
DM and its associated complications was at least US$376 billion [8]. 
This led to an increased interest in identifying the costs of DM in order 
to determine cost-saving solutions for the management of patients with 
DM. Such aims can be achieved by reviewing studies that examine the 
cost of DM.
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Ettaro et al. performed a systematic analysis of the medical care costs 
attributable to DM, reviewing approximately 30 published articles 
worldwide [3]. Nearly a decade later, as attention to the subject 
increases, we believe an updated review is merited, with Ettaro and 
colleagues’ study providing a useful framework. The present study 
aimed to review the recently published literature regarding the cost of 
DM. The objectives are two-fold: (1) to describe the methods used in 
the identified cost of DM studies and (2) to summarise their study 
findings regarding the economic impact of DM.
Methods
A systematic review was performed in accordance with a pre-specified 
protocol. Search results were screened for relevance according to the 




3. Studies that reported COI, healthcare expenditure, or resource 
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3. Economic evaluation of drug or other treatment (e.g. cost-
effectiveness analysis).
4. Only projected costs were provided.
5. Only one aspect of costs was provided (e.g. only inpatient costs).
6. No cost data reported.
7. Study population restricted to one hospital or clinic.
8. Conference abstracts, review papers, case reports, letters, 
comments, or editorials.
9. Animal or in vitro studies.
MEDLINE (via PubMed) and Scopus were the electronic databases 
searched in February 2012. The medical subject heading (MeSH) 
terms used for the search were “cost of illness” and “diabetes” and the 
keyword search terms were “burden of illness”, “cost”, “cost analysis”, 
“cost of disease”, “cost of illness”, “disease burden”, “economic burden”, 
“healthcare costs” and “diabetes”. Recently published studies and 
studies on Scopus were searched using only keywords as the new 
studies had not been indexed for MeSH and Scopus has no MeSH 
function. A Google Scholar search was also conducted with similar 
keyword search terms. In addition, a manual search of the 
bibliographies of the relevant articles identified was conducted. The 
search was limited to human studies published in English from January 
2007 to December 2011 and confined to those addressing costs 
among large populations, such as nations or insurance pools.
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Screening and data extraction
To evaluate the relevance of the articles retrieved from the literature 
search, two tiers of screening were performed by two trained 
reviewers. In the first step, only the articles with the words "costs" and 
"diabetes" or similar words in the title were included. In the second 
step, the two reviewers independently read and evaluated the abstract 
and, if necessary, the full texts of all the articles that passed the first 
round of screening based on the inclusion and exclusion criteria. In 
circumstances of uncertainty or discrepancy between the two 
reviewers, a discussion was held and, if necessary, a third reviewer's 
opinion was sought until a consensus was reached.
Essential information about the study methods and findings were then 
extracted from the articles that passed the two-step screening process 
and are summarised in Tables 2.1-2.3. For studies that presented both 
current and projected cost estimates, only current estimates were 
reported. Studies reporting excess costs due to DM and its
complications were also reviewed and summarised in Tables 2.4 and 
2.5 respectively. As an effort to ascertain the accuracy and 
completeness of the information retrieved, we emailed a summary 
information sheet to all the corresponding authors of the studies. The 
information sheet included all the information extracted from each 
study (e.g., year of costing, currency used and type of DM) by the 
investigators of the present review study. The information sheet was 
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then sent to the corresponding authors of each study to verify the 
accuracy of the information extracted. The authors were asked to reply 
with tracked changes if there was any error or misinterpretation. As 
different currencies were used in the cost estimates, cost values were 
converted to US dollars using the FX currency converter for 
comparison [73].
Results
The initial search strategy yielded 5493 studies, from which 1502 
duplicates were removed (Figure 2.1). Of the remaining 3991 articles, 
429 passed the first level of screening and 400 of those were excluded 
at the second screening, leaving 29 articles for data extraction. During 
data extraction, the bibliographies of the 29 articles were searched 
manually and one additional article that met the selection criteria was 
found, giving the total of 30 articles included in this review. 
Characteristics of COI articles
Table 2.1 summarises the methods and major findings of the 30 
articles reviewed. One third of the studies (n = 10) were conducted in 
the United States (U.S.) [24, 74-82] and the others were conducted in 
the WHO African region [19], Brazil [83], Canada [84], the Caribbean 
region [85], China [54], Germany [86, 87], Greece [88], India [89, 90], 
Iran [91, 92], Japan [93], the Netherlands [94], Norway [95], Sudan [96], 
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Sweden [97-99] and the United Kingdom [100]. Approximately half of 
the studies (n = 14) estimated both the overall direct and indirect costs 
of DM, with two studies also providing an estimate of lifetime costs [24, 
81]. Direct costs were included in all but one study where only 
incremental cost was reported. Indirect costs were reported in thirteen 
studies and intangible costs were estimated in only one study [90].
Furthermore, eight studies extrapolated the cost estimates to the 
national population.
Amongst the reviewed studies, the societal perspective was the most 
commonly taken (n = 11), followed by the healthcare system (n = 7) 
and third-party payer perspective (n = 7). Most authors did not explicitly
state the perspective taken. More than half of the reviewed studies 
included both type 1 and 2 DM patients (n = 17). The human capital 
approach was used in a majority of the studies (n = 10) that included 
indirect cost estimates. Moreover, most employed a retrospective (n = 
18) and prevalence-based (n = 28) study design, while two [24, 80]
adapted a Markov model to estimate costs.
Healthcare cost components
The healthcare components considered in the direct and indirect cost 
estimates varied among the studies (Tables 2.2 and 2.3). For direct 
cost estimation, most studies included costs associated with hospital 
inpatient care, physician services and drugs.  In those studies that 
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reported indirect cost estimates, all but two included costs associated 
with absenteeism and more than half took into account disability and 
premature mortality. Only three studies considered the foregone 
earnings as a result of DM-related presenteeism. 
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Figure 2.1: Flowchart of the number of articles retrieved from literature 
search and selection process                                                       
*Includes articles that did not fall into the above exclusion categories.                                                              
Google scholar/hand 
searches = 1 
Irrelevant studies or met 
exclusion criteria = 400
Cost-effectiveness analysis = 153 
Diabetes complications = 80
Medications related = 72
Others* = 90
Duplicate = 4
Non-English language = 1
Final studies included = 30
Total Records Identified = 5493




Removal of duplicates = 1502
Step 1: Studies screened by title = 3991
Include articles with the terms “cost” and 
“diabetes” in their titles
Irrelevant records excluded = 3562
Step 2: Studies screened by abstract /full 
text and inclusion/exclusion criteria = 429
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Table 2.1: Characteristics of cost-of-illness studies for diabetes mellitus, arranged by alphabetical order & reflecting costs incurred in the year stated











Total costs* Direct costs* Indirect costs*
% %
Abdulkadri et al. [85] 
(2001)
Caribbean 
region              
(4 countries 
included)
1 & 2 Ministry of 
Health data
360,002 R/PB Societal US$753mil 
(US$624.9mil)




United States 1 & 2 Multiple data 
sources
17,486 R/PB Healthcare 
system 
US$174bil US$116bil 66.7 US$58bil 33.3
Athanasakis et al. [88] 
(2007)
Greece 2 Medical 
records




Bahia et al. [83]                  
(2007)
Brazil              
(8 cities 
included)
2 Patient survey 
& medical 
records






US$2,108/pt US$1,335/pt 63.3 US$773/pt 36.7
Balu [75]                                           
(2004)
United States 1 & 2 National 
survey
13,922,448 R/PB Societal US$82.2bilb
(incremental direct costs 
comparing DM & no DM)
Bogner et al. [76]                 
(2000 & 2001)
United States 1 & 2 Insurance 
claims
971 R/PB Healthcare 
system 
US$10,566/pt
Bolin et al. [97]                       
(1987 & 2005)
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Table 2.1: Characteristics of cost-of-illness studies for diabetes mellitus, arranged by alphabetical order & reflecting costs incurred in the year stated











Total costs* Direct costs* Indirect costs*
% %




1 & 2 Insurance 
claims




Currie et al. [100]            
(1997-2007)
















Durden et al. [78]                    
(2000 & 2005)






R/PB Employer US$12,423/pt (2000); 
US$12,733/pt (2005)
Elrayah-Eliadarous 




2 Patient survey 822 CS/PB Patient US$175/pt
Esteghamati et al. [91] 
(2004-2005)














Fu et al. [79]                             
(2004 & 2006)
United States 1 & 2 National 
survey
4,233 CS/PB Societal US$13,130/pt US$10,845/pt 82.6 US$2,285/pt 17.4












US$2.7bilb or lifetime 
costs of US$27,140/pt 
(societal)
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Table 2.1: Characteristics of cost-of-illness studies for diabetes mellitus, arranged by alphabetical order & reflecting costs incurred in the year stated











Total costs* Direct costs* Indirect costs*
% %
Huang et al. [80]             
(Multiple years)





US$113bil or US$45bil 
for Medicare users
Javanbakht et al. [92] 
(2009)









49.3 US$864.8/pt or 
US$1.7bilb
50.7




1 & 2 Multiple data 
sources




INT$8.1bil (US$8.1bil) 31.8 INT$17.4bil 
(US$17.4bil)
68.2
Köster et al. [86]                 
(2000-2007)












Kumar et al. [89]                          
(2005)
Delhi, India 2 Community 
survey 
819 CS/PB Patient US$150/pt
Martin et al. [87]                           
(1995-2003)
Germany 2 Public health 
insurance 
database
3,142 R/IB Third-party 
payer
€3,210/pt 
(US$4,269.6/pt) for the 
mean observation 
period of 6.5yrs 
Nakamura et al. [93]                       
(1990-2001)
Shiga, Japan 1 & 2 Insurance 
claims
138 P/PB Third-party 
payer
US$328/pt/month





1 & 2 Administrative 
databases
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Table 2.1: Characteristics of cost-of-illness studies for diabetes mellitus, arranged by alphabetical order & reflecting costs incurred in the year stated











Total costs* Direct costs* Indirect costs*
% %




2 Multiple data 
sources
8,230 R/PB Healthcare 
system
€3,602/pt (US$4,791/pt)
Solli et al. [95]                                
(2005)












€222.4mil (US$295.8mil) 76 €70.1mil 
(US$93.2mil)
24.0
Tao et al. [81]                                  
(1999-2005)
United States 1 National 
surveys




lifetime costs of 
US$422.9bil
US$9,868/pt; US$6.9bil 




lifetime costs of 
US$289.2bil 
52.1
Tharkar et al. [90] 
(2009)
Chennai, India 2 Patient 
survey







Tunceli et al. [82] 
(2007)













T2: US$8,070/pt (by 
matched cohort cost 
estimation method)
van der Linden et 
al. [94] 
(2000-2004)












or €1.4bilab (US$1.9bil) 
(2004)
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Table 2.1: Characteristics of cost-of-illness studies for diabetes mellitus, arranged by alphabetical order & reflecting costs incurred in the year stated











Total costs* Direct costs* Indirect costs*
% %
Wang et al. [54]                       
(2007)




2,040 CS/PB Patient US$1707.8/pt or 
US$26.0bilb
US$1501.7/pt 87.9 US$206.1/pt 12.1





1 & 2 Administrative
database
20,876 CS/PB Government €4,474/pta
(US$5,950.8/pt)
* Cost converted to US-dollar; costs may not add up to exact amount due to rounding to one decimal place.
a Cost figures standardised to match age and gender distribution in the overall population.
b Cost figures for the entire country’s population.
bil=billion; CS=cross-sectional; DM=diabetes mellitus; IB=incidence-based; INT=international dollars; mil=million; MM=Markov modeling; NA=not applicable; P=prospective; 
PB=prevalence-based; pt=patient; R=retrospective; T1=type1; T2=type 2; yr=year.
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Table 2.2: Components of direct healthcare costs for diabetes mellitus



























Abdulkadri et al. [85]    
American Diabetes 
Association [74]        
Athanasakis et al.
[88]
   
Bahia et al. [83]       
Balu [75]     
Bogner et al. [76]        
Bolin et al. [97]   
Buescher et al. [77]      
Currie et al. [100]  
Durden et al. [78]     
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Table 2.2: Components of direct healthcare costs for diabetes mellitus





























   
Esteghamati et al. [91]         
Fu et al. [79] NR NR NR NR NR NR NR NR NR NR NR NR NR NR
Gonzalez et al. [24]     
Huang et al. [80]      
Javanbakht et al. 
[92] 
        
Kirigia et al. [19]      
Köster et al. [86]            
Kumar et al. [89]     
Martin et al. [87]   
Nakamura et al. [93] NR NR NR NR NR NR NR NR NR NR NR NR NR NR
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Table 2.2: Components of direct healthcare costs for diabetes mellitus



























Pohar & Johnson [84]  
Ringborg et al. [98]    
Solli et al. [95]        
Tao et al. [81]      
Tharkar et al. [90]        
Tunceli et al. [82]    
van der Linden et 
al. [94]                       
 
Wang et al. [54]      
Wiréhn et al. [99] 
      
a Includes either inpatient, outpatient or both
NR=not reported
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Table 2.3: Components of indirect healthcare costs for diabetes mellitus
Study                     Absenteeism Presenteeism Permanent disability Early retirement Premature Mortality
Abdulkadri et al. [85]     
American Diabetes Association [74]     
Bahia et al. [83]     
Bolin et al. [97]     
Esteghamati et al. [91]     
Fu et al. [79]     
Gonzalez et al. [24]     
Javanbakht et al. [92]     
Kirigia et al. [19]     
Solli et al. [95] NA NA   
Tao et al. [81]     
Tharkar et al. [90]     
Wang et al. [54]                   
NA=not available
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Cost of DM
Direct and indirect costs of DM
The costs of DM reported by different studies varied significantly (Table 
1). The annual direct costs for the total population in country ranged 
from an annual total of US$112.4 million in Iran to US$116 billion in the 
U.S. and from a per patient per year (pppy) of US$150 in India to 
US$14,060 in the U.S. Notably, there was a substantial difference in 
cost estimates between the two studies done in India [89, 90]. The 
direct costs were US$150 pppy for the study conducted in Delhi and 
US$525.5 pppy for the study conducted in Chennai. Furthermore, eight 
out of the thirteen studies that included both direct and indirect costs 
suggested that direct costs were higher than indirect costs. The 
general consensus from half of the studies (n=10) [54, 74, 76, 78, 81, 
86, 90, 95, 98, 99] that included inpatient costs, physician services and
medications was that inpatient costs was the major contributor to direct 
costs.
Excess cost of DM versus non-DM
Diabetes-related excess costs were reported in thirteen studies, with 
eight that included a matched control group (Table 2.4). The difference 
between DM patients and non-DM ranged from US$123.1 to 
US$10,837 pppy; the excess cost ratio between the two groups ranged 
Chapter 2. COI studies of DM: a systematic review                                            Ng, CS
37
from 1.5 to 4.4. Most studies included all age groups of patients and
the cost ratio was generally consistent among different age groups. 
The cost ratio was estimated to be approximately 2 in both studies that 
only included patients more than 40 years of age [76, 93]. In addition, it 
was reported in eight studies that additional inpatient hospital costs 
accounted for the majority of the excess costs in patients with DM.
Excess cost of DM complications versus no complications
The incremental costs of DM complications (Table 2.5) were reported 
in four studies, with different numbers of complications analysed in 
each. The cost ratio for a patient with DM complications to a patient 
without DM complications ranged from 1.9 to 2.1 [79, 91]. Three 
studies [54, 79, 90] did not have a matched control group, while two 
studies [54, 90] estimated the excess cost of three or more DM 
complications, resulting in higher cost ratios.
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Table 2.4: Annual medical costs for individuals with and without diabetes mellitus and excess cost of individuals with diabetes mellitus
Study                      
(year of costing)
Country DM type Study population                      Total medical costs*a
with DM                              without DM                          Excess costs of 
DM*a
























Bogner et al. [76]       
(2000 & 2001)
United States 1 & 2 ≥ 65 years of age US$10,566 US$5,450 US$5,116 1.9 NM




1 & 2 All ages T1: £742 (US$1,180);
T2: £602 (US$957.4) 
(1997); T1:  £1,323 
(US$2,104); T2:  £1,080 
(US$1,717.6) (2007)
T1: £254 (US$406.1); 
T2: £389 (US$621.9) 
(1997); T1: £362 














Durden et al. [78]     
(2000 & 2005)










[91]                              
(2004-2005)
Tehran, Iran 1 & 2 All ages US$191.9b US$68.8b US$123.1b 2.8 M
Köster et al. [86]         
(2000-2007)













Nakamura et al. [93] 
(1990-2001)
Shiga, Japan 1 & 2 40-69 years of age US$328/month US$162/month US$166/month 2 NM
Pohar & Johnson [84] 
(2001)
Canada 1 & 2 All ages CAD$3,622 (US$3,625.9) CAD$875 (US$877.4) CAD$2,747 
(US$2,748.5)
4.1 M
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Table 2.4: Annual medical costs for individuals with and without diabetes mellitus and excess cost of individuals with diabetes mellitus
Study                      
(year of costing)
Country DM type Study population                      Total medical costs*a
with DM                              without DM                          Excess costs of 
DM*a
Cost ratio of 
DM to non-DM
M/NM
Tao et al. [81]               
(1999-2005)
United States 1 All ages US$9,868 US$3,580 US$6,288 2.8 M
Tunceli et al. [82]     
(2007)









van der Linden et 
al. [94]                       
(2000-2004)



















1 & 2 All ages €4,474b (US$5,950.8) €2,504b (US$3,339.8) €1,971b (US$2,611) 1.8 NM
* Cost converted to US-dollar; costs may not add up to exact amount due to rounding to one decimal place.
a Costs are per person per year, unless otherwise stated.
b Cost figures standardised to match age and gender distribution in the overall population.
c Cost figures for the entire country’s population.
bil=billion; DM=diabetes mellitus; M=matched; mil=million; NA=not available; NM=non-matched; NR=not reported; T1=type1; T2=type 2; yr=year.
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Table 2.5: Annual medical costs for individuals with and without diabetes mellitus complications and excess cost of individuals with diabetes mellitus complications
Study                     
(year of costing)
Country DM type Study population              Total medical costs*a
With DM 
complications      
without DM 
complications      
Excess costs of 
DM complications*a






Esteghamati et al. [91] 
(2004-2005)
Tehran, Iran 1 & 2 All ages US$238.7b US$125.8b US$112.9b 1.9 M
Fu et al. [79]                  
(2004 & 2006)





Tharkar et al. [90]      
(2009)
Chennai, India 2 All ages US$672.6 for ≥ 3 
complications
US$134.9 US$537.7 5 NM





2 ≥18 years of age US$4632.3 for ≥ 4 
complications
US$897.4 US$3,734.9 5.2 NM
* Cost converted to US-dollar; costs may not add up to exact amount due to rounding to one decimal place.
    a Costs are per person per year, unless otherwise stated.
b Cost figures standardised to match age and gender distribution in the overall population.
DM=diabetes mellitus; M=matched; MVC= macrovascular complications; NM=non-matched.
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Discussion
Over the last three decades, numerous economic studies of diabetes 
have suggested that the disease is associated with a large economic 
burden. This present systematic review aimed to identify the evidence 
and summarise the findings concerning the economic burden of DM. 
The most notable findings in this review is that the methodology used 
to derive cost-of-diabetes estimates varied considerably among the 30 
studies examined and that the most critical determinant of direct costs 
appears to be the use of inpatient care.
In our review, the cost of DM was estimated to account for 1.0% [97] to 
8.7% [92] of a country’s total healthcare expenditures. Ideally, the 
estimates of health care costs should also take into account 
undiagnosed DM patients. While these patients may not be receiving 
treatment for diabetes, they may be incurring additional healthcare 
costs compared to those without diabetes. The fact that people with 
diabetes already have complications at the time of diagnosis suggests 
that DM-related costs are present among the undiagnosed [101]. 
Therefore, overlooking these patients often leads to an underestimation 
of total costs that result from diabetes [77, 79, 92, 101]. According to 
the International Diabetes Federation, approximately 45.8% of DM 
patients were undiagnosed [102]. As such, the actual economic burden 
of DM may have been even more substantial than that estimated in the 
studies reviewed.
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Despite the common opinion that indirect costs far exceed direct costs 
[20, 103], the findings of this review were less decisive. An explanation 
for the higher direct costs reported in eight studies may be that the 
costs of hospitalisation and medications have risen significantly, 
overshadowing indirect costs like absenteeism. In addition, in two U.S. 
studies, inpatient costs alone accounted for 50.0% to 75.4% of the total 
cost [74, 76]. This finding was consistent with other COI studies [81, 82, 
86, 91, 95, 98, 103, 104], indicating that the cost of hospital care has 
increased markedly over recent decades. This is not surprising given 
the inherent high costs associated with inpatient care versus 
ambulatory care. 
Among the studies reviewed, only eleven studies estimated the COI of 
DM from a societal perspective. Although COI estimates from a 
narrower perspective are without a doubt informative and serve a 
specific purpose, these studies are of limited value when the aim is to 
understand the economic burden of a disease from a societal 
perspective [20]. For example, studies taking the third-party payer 
perspective usually do not consider direct non-medical costs or indirect 
costs, as these components are not covered by an insurance plan
[105].
Most of the reviewed studies used health insurance claim databases 
for direct medical cost estimation, an approach that is limited by its 
inability to capture out-of-pocket costs. In order to include these costs 
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and other DM-related expenses that are missed in most studies, a 
small number of studies also collected data from patient surveys or
interviews. These retrospective and prevalence-based analyses, which 
were the most commonly used approaches, also have inherent 
limitations. These approaches often use large administrative databases, 
thus making it difficult to isolate the medical costs directly attributable 
to DM, because patients with DM typically present comorbid conditions 
[106, 107].
The number of direct and indirect cost categories that were considered 
by a study was found to have an influence on the magnitude and 
precision of the study’s costs estimates [20]. While most studies 
included common costs such as inpatient, outpatient and medication 
costs, only a few considered costs associated with allied health, 
rehabilitation or nursing homecare. Studies limited to fewer categories 
are likely to have underestimated the actual costs of DM [20]. It is also 
noteworthy that most studies that dealt with patient-level data included 
premature mortality in estimating indirect costs, which may have 
contributed to the discrepancy in cost estimates and also made the 
comparison difficult. In order to make comparison and interpretation 
possible, COI studies need to be more explicit about the types of costs 
incorporated and how they were calculated [1, 104].
Furthermore, the reviewed studies included different population groups, 
which may have also influenced cost estimates. Some studies focused 
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on type 2 DM only, while others examined both type 1 and type 2 
and/or other DM-related complications. For example, as one would 
expect, DM with related complications tend to be more costly than DM 
alone, due to the frequency and duration of hospitalisations. This 
difference may have also accounted for the large discrepancy in costs 
between the two studies [89, 90] conducted in India as the one that 
included DM complications resulted in higher costs.
Ettaro et al. explained that excess cost due to DM was expected to 
differ by age, with higher excess costs more commonly found in 
younger age groups [3]. However, in our findings, there was no 
significant difference in the cost ratio and excess costs of DM in the 
studies of only the elderly population compared to those that included 
all age groups. The reason that younger age groups did not report 
higher costs might be explained by better access to preventative care 
for DM complications or that the higher cost in the elderly population 
could be explained by a decrease in the use of effective healthcare 
resources. Based on the cost ratio, it is clear that a substantial amount 
of DM-attributed health expenditure and resource use is for DM 
complications, with most reviewed studies reporting more than a 
twofold increase when compared to patients with no complications. 
This finding highlights the importance of maintaining good glycemic 
control in order to prevent or reduce complications and consequently to 
decrease their associated costs. It was also found that the cost ratio of 
DM to non-DM individuals was between 2 and 3. The highest excess 
Chapter 2. COI studies of DM: a systematic review                                            Ng, CS
45
cost ratio of 4.1 reported in Pohar and Johnson’s study may be 
attributed to the study population being an ethnic minority, a group 
more likely to live rurally, with limited access to primary health care 
physicians. Consequently, these patients might only seek medical care 
when the disease has progressed to a later stage, which typically 
incurs higher overall costs.
The previous DM COI systematic review identified the highest total cost 
attributed to DM to be US$137.7 billion in the U.S. [108]. Similarly, our 
study observed the highest total cost of DM to be US$174 billion in the 
U.S. in 2007. This 26.0% increase in cost falls within acceptable 
parameters, considering inflation and rising healthcare costs across a 
span of 12 years. For excess costs attributed to DM, Ettaro and 
colleagues [3] found a cost ratio of 2 to 5 whereas in the present study, 
we calculated a similar cost ratio of 1.5 to 4.4. Moreover, the 
healthcare cost components included in Ettaro et al’s study [3] were 
similar to components in this review, with inpatient, outpatient and 
medication often reported in cost-of-diabetes studies.
The present study incorporated a systematic search, a dual review of 
all the included studies and a comprehensive inclusion and exclusion 
criteria with the aim of reducing potential bias in the study selection. It 
should be noted, however, that the findings of this study were limited 
by examining only two databases and the time period of the last 5 
years. It is likely that a broader search of multiple databases without 
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language or date restrictions would yield COI studies with different 
results. Furthermore, the diversity of the sampled populations and the 
scope of resource items included made difficult the comparison of cost 
estimates.  
COI studies are used to educate and inform policymakers by providing 
fiscal information to support their decision-making processes. It is 
essential that COI studies be adequately designed to measure the 
economic burden of a disease. In addition, the design of such studies 
should be able to account for the variability in costs identified [1, 109, 
110] and their results should be interpreted with caution [21]. Therefore, 
we recommend establishing agreement among researchers on the 
methodological principles of cost studies [111]. Moreover, guidelines or 
checklists need to be developed to evaluate the quality of COI 
analyses in order to ensure standardisation of COI studies.
Conclusion
Despite the diversity of methods used, there is a general consensus in 
the existing literature that DM places a significant financial burden not 
only on the healthcare system, but also on the individual and society as 
a whole. A few major findings should be highlighted. First, 
hospitalisation is the most important direct cost drivers. Second, a lack 
of standardised COI methods and study designs made direct 
comparisons difficult. 
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Understanding the magnitude of the burden of DM is important for 
public policymakers, that is, those who are responsible for establishing 
health care priorities and allocating scarce resources to yield the 
greatest benefits. In order to make an understanding of costs easier to 
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Chapter 3 Direct Medical Cost of Type 2 Diabetes in 
Singapore
Introduction
Globally, the total number of people with DM is projected to rise from 
171 million in 2000 to 366 million in 2030 [35]. There is a growing 
epidemic of diabetes mellitus, type 2 in particular, in the Asia-Pacific 
region [45, 46]. According to current estimates, the DM population in 
this region is the largest in the world, with approximately 47.3 million, 
which is 46% of the global burden of this disease [70]. In Singapore, as 
in many developed countries, DM is a growing public health problem. 
The prevalence of DM has risen to a 12.3% in 2013, from 8.2% in 2004 
and 9% in 1998 [40, 41], surpassing other Asian countries such as 
Hong Kong (9.5%), Japan (7.2%) and Taiwan (5.7%) [112]. Moreover, 
DM is the tenth leading cause of death in Singapore, accounting for 1.7% 
of total deaths in 2011 [113].
Diabetes is a chronic medical condition associated with numerous 
complications that makes it a substantial economic burden incurred by 
individuals, healthcare systems and society as a whole [3]. In 2007, the 
global health expenditure to treat and prevent DM and its complications 
was estimated to be at least US$232 billion [112]. Depending on 
available treatments and local prevalence, the direct costs of DM 
consume from 2.5% to 15.0% of annual healthcare budgets [54].
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Despite the large number of people with DM, the financial burden in 
Singapore attributable to DM has not been investigated. Because 
T2DM accounts for approximately 90% of DM cases and its prevalence 
increases with ageing, understanding the patterns of resource use and 
cost associated with T2DM is becoming increasingly important for 
policymakers and budget planners. Therefore, this study aims to 
identify the total direct medical cost of T2DM in Singapore and to 
examine the relationship between direct medical costs and individual 
demographic characteristics, DM interventions (exercise or diet, taking 
oral medications only, taking insulin only and taking both insulin and 
oral medications), disease control, complications and comorbidities.
Methods
Study design 
This study adopted a prevalence-based ‘epidemiological’ approach, 
employing a bottom-up methodology to estimate different cost 
components. The prevalence approach can yield more precise 
estimates because it is based, at least in principle, on observed costs 
rather than projected ones [114]. The perspective for this study was 
that of the National Healthcare Group (NHG) institutions.  
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Data Source 
This was a cross-sectional study of T2DM patients who had received 
care in any of the NHG institutions in 2010. The NHG is public funded 
and provides inpatient and ambulatory care (primary care, specialist 
outpatient and 24-hour emergency) services through a network of 3
acute hospitals, 1 national center, 9 primary care clinics and 3 specialty
institutes serving the population in the central and western parts of 
Singapore. The 9 primary care clinics, also known as polyclinics, had a 
service load of 3.7 million attendances in 2010, which accounted for 
60% of all public sector primary care attendances [115]. Data was
drawn from the NHG Chronic Disease Management System (CDMS), 
which serves as an operational disease registry within the NHG. The 
CDMS was commissioned in 2007 to enhance the delivery of care for 
patients with DM and to facilitate greater efficiency in outcome 
measurement. It links key clinical data of patients with DM across the 
NHG healthcare cluster, including records of visits to physicians, 
nurses, and allied health professionals, as well as medication and
laboratory test records [116]. In addition, it also includes registration 
and financial cost data related to the care of chronic diseases.
Patient selection
Patients with T2DM were identified using the International
Classification of Diseases Ninth Revision (ICD-9-CM) diagnostic code 
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of 250 as primary or secondary diagnosis, or using pharmacy
medication records or laboratory data in the CDMS. Diabetes 
complications and comorbidities were also identified using ICD-9-CM 
codes, while medications and laboratory data were based on inpatient 
and outpatient encounters at the hospital or outpatient clinics that were 
registered with the CDMS. 
This study included patients who satisfied at least one of the following 
three criteria: (1) assigned ICD-9-CM code of 250; (2) attended 
treatment for DM for 1 year in any NHG institution; or (3) prescribed 
any anti-diabetic medication. Patients with type 1 DM and women with 
gestational diabetes were excluded.
Laboratory-derived measures related to DM
Measures for DM-related physical examinations were included and 
categorised as follows: (1) body mass index (BMI) (kg/m2): <18.50 = 
underweight; 18.50-24.99 = normal; >25.00 = overweight and obese 
[117], (2) glycated haemoglobin (HbA1c) (%): ≤7.0 = good disease 
control; 7.1-8.0 = sub-optimal disease control; >8.0 = poor disease 
control, (3) low-density lipoprotein cholesterol (LDL-c) (mmol/L): <2.6 = 
optimal; 2.6-4.0 = near optimal; >4.0 = high, (4) urine albumin-to-
creatinine ratio (UACR) (albumin/24h): <30mg = normal; 30-299mg = 
microalbuminuria; >300mg = macroalbuminuria [118, 119].
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Estimation of costs
Direct DM-related costs were classified by the type of service, including 
inpatient hospitalisation, A&E and ambulatory outpatient care 
(physician visits, allied health visits, laboratory tests and medications). 
Allied health visits include foot screening, eye screening, dietary 
services and health education. The total medical costs were estimated 
by the total before-subsidy charges, which is the total medical bill 
before any deduction for government subsidies or insurance claims. 
Discounting was not required because only one-year cost was 
estimated. All costs reported were in Singapore currency (S$) for year 
2010 prices. 
The cost of inpatient care and A&E services were estimated by the total 
charge based on the length of stay and resources used. Any A&E visits 
that resulted in hospitalisation were included as inpatient care costs. 
Physician visits included visits to primary care clinics (polyclinics) and 
specialist outpatient clinics (SOC) (hospitals). Unit prices used in the 
estimation were equal to the standardised rate for physician visits at all 
NHG primary care clinics and hospitals. Therefore, costs were 
estimated by multiplying the number of physician visits by the unit cost 
of a visit. Unit prices for allied health visits, laboratory tests and 
medications were estimated via the same method. The cost for drugs 
other than anti-diabetic medications was not included. All unit costs 
were provided by the NHG and are in Singapore dollars. Direct non-
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medical costs, such as out-of-pocket expenses and indirect or 
productivity costs for loss of work were not included.  
Statistical methods
Healthcare cost data are often positively skewed because a relatively 
small proportion of patients incur extremely high costs [79, 92]. Such 
problems were dealt with by logarithmic transformation of the cost data 
[120]. Descriptive statistics (frequency, percentage, mean, median, 
standard deviation and 90th percentile) were used for demographic 
information and expenditures. To identify the factors affecting total 
costs, a multiple linear regression model was developed to evaluate 
the relationship of both demographic and clinical state variables 
(HbA1c, DM interventions, complications and comorbidities) to the total 
calculated expenditure. All statistical analyses were performed using 
Statistical Package for the Social Science (SPSS) version 21.0 (SPSS 
Inc., Chicago, IL, USA).
Results
Patient characteristics
A total of 98,592 patients in the NHG CDMS (2010) were identified as 
patients with DM. After applying the selection criteria and a systematic 
sampling, 500 patients were included in the analyses. The socio-
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demographic profile of the patients is shown in Table 3.1. The patients 
were equally distributed between the two genders (55.4% female). The 
mean (±SD) age was 69.0 ± 9.4 years, and most study patients were 
Chinese (77.6%) and non-smokers (89.8%). Although a greater 
proportion of patients was overweight (42.6%), most had good disease 
control (44.6%), optimal LDL-c (43.2%) and normal UACR (41.2%). Of 
the 69.2% of DM patients who were on anti-diabetic medications, the 
majority used oral medications (57.2%), while only 3% were treated 
with insulin and the remaining 9% used both insulin and oral 
medications. Nephropathy (57.2%) and cardiovascular conditions 
(34.2%) were common DM complications among the cohort. The 
distributions of subgroups were similar between patients with at least 
one inpatient visit and those without any inpatient visit. 
Annual costs of diabetes
The mean annual direct cost was S$2,034.6 (US$1.0 = S$1.3 as of 31 
December 2010) [73], of which S$1,237.2 accounted for by inpatient 
services, S$84.2 by A&E services and S$713.2 by outpatient services 
(Table 3.2). Of the total healthcare expenditure, the main cost driver 
was inpatient costs (60.8%), while A&E services (4.1%) were only a 
small portion of the total costs. The major source of costs for outpatient 
services was physician visits, which accounted for 22.6% of the total 
healthcare expenditure and 64.0% of total outpatient expenditure 
(Figure 3.1). 
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Patients with at least one inpatient admission had higher mean total 
costs (S$8,787.8) than those who had no inpatient admission 
(S$690.5), with the bulk of costs resulting from inpatient services 
(S$7,453.3). Conversely, patients with no inpatient visit had a 
substantially higher proportion of overall outpatient costs.
Factors affecting the total costs 
Using multiple linear regression with log transformation, the total cost 
of DM was significantly associated with DM interventions (taking insulin 
only or both oral medications and insulin) and DM-related 
complications (cerebrovascular, cardiovascular, and peripheral 
vascular diseases and nephropathy). This model explained 23.0% of 
the variance in costs (Table 3.3). Age, gender, race, smoking status, 
disease control, taking only oral medication, having retinopathy and 
comorbidities were not independently associated with cost. The 
combination of oral medications and insulin resulted in an increment in 
annual total cost (17.5%, p=0.047), while the use of only insulin led to a 
higher increment (53.2%, p<0.001) when compared with patients who 
were only on dietary control and healthy lifestyle advice alone. Taking 
the absence of complications as reference, the cost of DM was higher 
when complications were present except in the case of retinopathy.  
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Table 3.1: Socio-demographic and clinical characteristics of patients with diabetes mellitus, CDMS 2010 
Characteristic n (%)* or mean ± standard deviation
Overall (n=500)1
≥1 inpatient visit 
(n=83)2
0 inpatient visit 
(n=417)3
Individual level factors
Age (years) 69.0 ± 9.4 71.7 ± 9.5 68.8 ± 9.3
Gender
Female 277 ( 55.4 ) 45 ( 54.2 ) 185 ( 55.6 )
Male 223 ( 44.6 ) 38 ( 45.8 ) 232 ( 44.4 )
Race
Chinese 388 ( 77.6 ) 61 ( 73.5 ) 327 ( 78.4 )
Malay 57 ( 11.4 ) 10 ( 12.0 ) 47 ( 11.3 )
Indian 34 ( 6.8 ) 6 ( 7.2 ) 28 ( 6.7 )
Others 21 ( 4.2 ) 6 ( 7.2 ) 15 ( 3.6 )
Smoking status
Non-smoker 449 ( 89.8 ) 75 ( 90.4 ) 374 ( 89.7 )
Smoker 51 ( 10.2 ) 8 ( 9.6 ) 43 ( 10.3 )
Physical examination
BMI (kg/m2) (n=378)1 (n=45)2 (n=333)3 26.1 ± 4.7 26.0 ± 5.0 26.1 ± 4.6
Underweight 7 ( 1.4 ) 2 ( 2.4 ) 5 ( 1.2 )
Normal 158 ( 31.6 ) 16 ( 19.3 ) 142 ( 34.1 )
Overweight 213 ( 42.6 ) 27 ( 32.5 ) 186 ( 44.6 )
Blood pressure (mmHg) (n=414)1 (n=56)2 (n=358)3
Systolic 132.2 ± 14.0 134.9 ± 17.1 131.8 ± 13.4
Diastolic 70.4 ± 7.5 71.2 ± 9.3 70.3 ± 7.2
HbA1c (%) (n=441)1 (n=73)2 (n=368)3 7.3 ± 1.2 7.3 ± 1.5 7.3 ± 1.2
Good disease control 223 ( 44.6 ) 37 ( 44.6 ) 186 ( 44.6 )
Sub-optimal disease control 134 ( 26.8 ) 19 ( 22.9 ) 115 ( 27.6 )
Poor disease control 84 ( 16.8 ) 17 ( 20.5 ) 67 ( 16.1 )
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Table 3.1: Socio-demographic and clinical characteristics of patients with diabetes mellitus, CDMS 2010 (continued)
Characteristic n (%)* or mean ± standard deviation
Overall (n=500)1
≥1 inpatient visit 
(n=83)2
0 inpatient visit 
(n=417)3
LDL-c level (mmol/L) (n=398)1 (n=61)2 (n=337)3 2.6 ± 0.8 2.7 ± 1.1 2.6 ± 0.7
Optimal 216 ( 43.2 ) 35 ( 42.2 ) 181 ( 43.4 )
Near optimal 169 ( 33.8 ) 23 ( 27.7 ) 146 ( 35.0 )
High 13 ( 2.6 ) 3 ( 3.6 ) 10 ( 2.4 )
Serum creatinine (μmol/L) (n=424)1 (n=81)2 (n=343)3 102.1 ± 87.6 137.0 ± 145.4 93.9 ± 64.8
UACR (n=321)1 (n=39)2 (n=282)3
Normal 206 ( 41.2 ) 15 ( 18.1 ) 191 ( 45.8 )
Microalbuminuria 94 ( 18.8 ) 20 ( 24.1 ) 74 ( 17.7 )
Macroalbuminuria 21 ( 4.2 ) 4 ( 4.8 ) 17 ( 4.1 )
Diabetes intervention
Diet or exercise only 154 ( 30.8 ) 27 ( 32.5 ) 127 ( 30.5 )
Oral anti-diabetic medication only 286 ( 57.2 ) 42 ( 50.6 ) 244 ( 58.5 )
Insulin only 15 ( 3.0 ) 8 ( 9.6 ) 7 ( 1.7 )
Oral and insulin 45 ( 9.0 ) 6 ( 7.2 ) 39 ( 9.4 )
Diabetes complications
Nephropathy 286 ( 57.2 ) 63 ( 75.9 ) 223 ( 53.5 )
Cardiovascular 171 ( 34.2 ) 49 ( 59.0 ) 122 ( 29.3 )
Retinopathy 75 ( 15.0 ) 24 ( 28.9 ) 51 ( 12.2 )
Peripheral vascular disease 73 ( 14.6 ) 27 ( 32.5 ) 46 ( 11.0 )
Cerebrovascular 71 ( 14.2 ) 32 ( 38.6 ) 39 ( 9.4 )
Diabetes comorbidity
Dyslipidaemia 483 ( 96.6 ) 77 ( 92.8 ) 406 ( 97.4 )
Hypertension 441 ( 88.2 ) 81 ( 97.6 ) 360 ( 86.3 )
* Percentages may not add up to 100% due to missing values
1 n = 500 otherwise stated in the brackets
2 n = 83 otherwise stated in the brackets
3 n = 417 otherwise stated in the brackets
BMI = body mass index, HbA1c = glycated haemoglobin, LDL-c = low-density lipoprotein cholesterol, UACR = urine albumin-to-creatinine ratio
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Table 3.2: Direct medical costs of diabetes mellitus paid by the hospital
Costs variables Total (S$) %* Mean SD Median 90th percentile
Overall (n=500)
Inpatient costs 618,622.0 60.8 1,237.2 ± 4,085.8 0.0 2,846.4
Accident & Emergency 42,084.4 4.1 84.2 ± 277.6 0.0 300.4
Outpatient costs 356,600.8 35.1
Physician visit 229,506.0 22.6 459.0 ± 396.8 325.0 974.0
Allied health service 10,061.0 1.0 20.1 ± 30.0 19.6 40.8
Laboratory tests 35,990.0 3.5 72.0 ± 52.5 68.9 114.3
Medications 81,043.9 8.0 162.1 ± 220.4 101.0 377.5
Total 1,017,306.2 2,034.6 ± 4,351.0 664.1 4,209.6
≥ 1 inpatient visit (n=83)
Inpatient costs 618,621.0 84.8 7,453.3 ± 7,395.5 3,740.5 16,858.9
Accident & Emergency 33,745.6 4.6 406.6 ± 550.2 301.2 722.4
Outpatient costs 77,021.4 10.6
Physician visit 57,851.0 7.9 697.0 ± 479.0 612.0 1,344.4
Allied health service 2,022.9 0.3 24.4 ± 50.0 0.0 52.3
Laboratory tests 5,523.2 0.8 66.5 ± 63.3 58.2 154.5
Medications 11,624.3 1.6 140.1 ± 232.2 62.0 302.4
Total 729,388.0 8,787.8 ± 7,660.1 5,160.4 18,322.6
0 inpatient visit (n=417)
Accident & Emergency 8,338.8 2.9 20.0 ± 88.9 0.0 0.0
Outpatient costs 279,579.4 97.1
Physician visit 171,655.0 59.6 411.6 ± 360.7 296.0 834.2
Allied health service 8,038.0 2.8 19.3 ± 24.1 19.6 35.4
Laboratory tests 30,466.7 10.6 73.1 ± 50.1 70.9 108.2
Medications 69,419.6 24.1 166.5 ± 218.0 114.7 386.7
Total 287,918.2 690.5 ± 481.3 588.2 1,200.6
* Percentages may not add up to 100% due to missing values
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Table 3.3: Factors influencing the total annual cost of diabetes (n=500)*
Characteristic β-coefficient 95% CI P value
Individual level factors
Age (per year increase) 0.000 -0.004 0.005 0.900
Gender
Male (reference)
Female 0.034 -0.047 0.114 0.412
Race 
Chinese (reference) 0.000
Malay 0.102 -0.021 0.225 0.104
Indian 0.039 -0.120 0.198 0.632
Others 0.143 -0.050 0.336 0.146
Smoking status
Non-smoker (reference)
Smoker -0.043 -0.178 0.091 0.528
Physical examination
HbA1c (%) (n=441)
Good disease control (reference)
Sub-optimal disease control 0.001 -0.097 0.098 0.989
Poor disease control 0.066 -0.055 0.187 0.286
Diabetes intervention
Diet or exercise only (reference)
Oral medication only 0.079 -0.024 0.182 0.132
Insulin only 0.532 0.276 0.788 <0.001
Oral and insulin 0.175 0.002 0.348 0.047
Diabetes complications (Absent reference)
Cerebrovascular 0.310 0.189 0.430 <0.001
Cardiovascular 0.150 0.054 0.245 0.002
Peripheral vascular disease 0.207 0.088 0.325 0.001
Nephropathy 0.123 0.005 0.240 0.041
Retinopathy 0.046 -0.070 0.161 0.436
Diabetes comorbidity
None (reference)
Either hypertension or dyslipidaemia 0.114 -0.101 0.328 0.298
Both hypertension and dyslipidaemia 0.071 -0.077 0.219 0.348
* n = 500 otherwise stated in the brackets
HbA1c = glycated haemoglobin
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Discussion
This prevalence-based cost-of-illness study involved a large captive 
population with T2DM in Singapore. The analysis was based on cost 
and administrative data retrieved from the NHG disease registry for 
2010. This is the first study to provide estimates of costs associated 
with diabetes care in Singapore. 
The cost per patient estimate in this present study was S$2,034.6 
(US$1,575.6), and this appears to be higher than the costs reported in 
other Asian countries. A study in India reported an estimate of 
US$525.5 per patient [90] while a study in China reported costs of
US$1,501.7 per patient [54] for the management of DM. However, the 
costs reported in these studies were presented without accounting for 
inflation or currency differences. Notably, hospital costs reported in the 
American and European continents were much higher than those 
obtained in this study [74, 86, 95]. Despite the cost differences, 
inpatient costs still remained the main cost driver of the total estimated 
expenditure, which was also noted in the earlier DM COI studies [81, 
86, 91]. Although the length of stay (LOS) was not reported in this 
study, often the high cost of inpatient services were often strongly 
correlated to LOS [121, 122], with higher LOS resulting in higher costs. 
This suggested that attempts to expedite services or reduce 
unnecessary utilisation of diagnostic tests to reduce LOS may be 
worthwhile in reducing overall costs.
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In terms of outpatients costs, physician services contributed to the bulk 
of the total expenditure, and this was understandable since the growth 
in the number of physicians and specialists have risen over the years 
to meet with higher patient demands [123]. In addition, the introduction 
of new medical technologies and prescription drugs have also shown
significant association with physician cost growth because consumers 
generally require physician visits to obtain diagnostic tests and 
prescriptions [123]. Because physicians are central to the healthcare 
system, efforts to contain physician spending reverberate through all 
healthcare services, especially since follow-ups are inevitable in 
chronic conditions such as DM. 
Results of regression analyses generally confirmed what might have 
been expected based on epidemiologic evidence in the literature [54, 
79, 83, 124, 125]. That is, known complications such as microvascular 
and macrovascular complications tend to increase the cost of care. On 
the contrary, comorbidities such as hypertension and dyslipidaemia did 
not have an association with overall cost. This result is surprising since 
cost-effectiveness and medication adherence studies [126-129] have 
reported that achieving lower levels of clinical parameters would lead to 
an increase in cost of care albeit increasing the quality-adjusted life 
years (QALY). 
Patients with sub-optimal and poor disease control had lower overall 
costs, which seems paradoxical. One might expect that DM patients 
Chapter 3. Direct medical cost of T2 DM in Singapore                                       Ng, CS
64
with higher HbA1c, would require more health services. This may be an 
indicator of barriers to healthcare and/or poor diabetes self-
management resulting in lower healthcare costs when compared to 
patients with good disease control. The importance of managing DM to 
prevent or delay complications requires effort [130] and good control of 
DM results in long-term cost savings due to fewer complications [131]. 
Furthermore, the use of insulin only or both insulin and oral 
medications were found to be associated with higher costs. Consistent 
with other studies, the most expensive component of total outpatient 
costs after physician costs were medications [74, 85, 86, 91]. This rise 
in cost indicated a growth in the consumption of prescription 
medications, which could be due to more patients being compliant with 
their medications. This compliance may result in better healthcare 
outcomes and reduce the need for physician visits [132, 133], which 
could ultimately lead to a net decrease in overall healthcare cost.
As a prevalence-based cost-of-illness study, the strength of this study 
lies in that all DM cases were included from a specified year, 
regardless of whether or not they were diagnosed before or during that 
year. This breadth allows for a cross-section of patients in various 
stages of the illness, since different severities of DM are associated 
with different costs. However, several limitations of this study should be 
noted. First, data was drawn from a healthcare database, hence relied 
on the accuracy and completeness of the records. The NHG CDMS 
has, however, been used in several studies and is recognised for
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providing well-validated and comprehensive data [115, 134]. Second, 
patients with undiagnosed diabetes as well as indirect/intangible costs 
and out-of-pocket expenses were not included, which has likely 
resulted in an underestimation of the true cost of diabetes. Lastly, the 
study population was relatively small and limited to the public 
healthcare sector in Singapore.
Conclusion
This study provided a comprehensive cost analysis of expenditures 
incurred in the treatment of the DM population in Singapore. The 
results indicated that both medications and DM complications were 
strong determinants of costs. As the prevalence of DM in Singapore 
continues to grow in the years to come, coupled with both improved 
medical treatment on the one hand and the increasing prevalence of 
obesity on the other, diabetes will continue to be a heavy burden on 
health budgets. Hence, as observed from the present findings, 
knowledge of the economic burden related to each T2DM complication 
and what drives cost can be useful in health-system reform that seeks 
to minimise the long-term economic burden of this growing epidemic.
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CHAPTER FOUR
Direct Medical Cost of Stroke in Singapore
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Chapter 4 Direct Medical Cost of Stroke in Singapore
Introduction
Globally, stroke is the second most common cause of death and one of 
the main causes of long term disability [135]. Approximately 16 million 
first-occurrence strokes occur around the world per year, accounting for
5.7 million deaths [36]. In 2010, stroke-related disability was judged to 
be the third most common cause of reduced DALYs [136]. Much of the
available epidemiologic data on stroke come from Europe, the United 
States and Australia, with little data from countries in Asia other than
China, India and Japan [50]. In Singapore, stroke is the fourth leading 
cause of death, accounting for 9.0% of total deaths in 2013. It has a 
prevalence of 3.7% and an incidence of 1.8 per 1,000 person-years 
and it is among the top 10 causes of hospitalisation [42, 43].
Stroke is a debilitating and costly chronic medical condition. Worldwide, 
stroke consumes about 2–4% of total healthcare expenditure, and in 
developed countries stroke accounts for more than 4% of direct 
healthcare costs [56]. The total annual costs have been variously 
estimated at US$40 billion in the United States [57], AUS$1.3 billion in
Australia [58], and £8.9 billion in the United Kingdom [59]. A study 
conducted in Singapore in 1996 estimated the mean direct cost for 
hospital care to be S$7,547, with ward charges accounting for the 
majority of the total cost [137].
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With a rapidly aging population, the number of elderly citizens in 
Singapore will likely triple to 900,000 by 2030, and a consequent 
increase in the prevalence of stroke is expected [138, 139]. It is timely 
to examine the factors influencing the cost of stroke in order to provide 
local information to the government, healthcare providers, and 
policymakers who are responsible for establishing healthcare priorities 
and taking advantage of potential savings. Their decisions will 
ultimately dictate how the economic burden of a disease is distributed.  
Therefore, this study aims to identify the total direct medical cost of the 
four main stroke types in Singapore: (1) ischaemic stroke (IS), (2) 
subarachnoid haemorrhage (SAH), (3) intracerebral haemorrhage (ICH) 
and (4) transient ischaemic attack (TIA) and also to examine the 
relationship between the total estimated costs and individual 
demographic characteristics, type of stroke, length of post-stroke 
period, complications and comorbidities. 
Methods
Study design 
This study adopted a prevalence-based epidemiological approach, 
employing a bottom-up methodology to estimate different cost 
components. The prevalence approach can yield more precise 
estimates because it ascertains the current economic burden of a 
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disease rather than projected ones [114] and is commonly used in 
illnesses that produce long-term sequelae [140]. The perspective for 
this study was that of the NHG institutions.  
Data source
This was a cross sectional study of stroke patients who had received 
care in any of the NHG institutions between January 1, 2006 and 
December 31, 2012. The NHG is an integrated public healthcare
delivery system which consists of 3 acute hospitals, 1 national center, 9 
primary care clinics and 3 specialty institutes. The NHG provides 
primary care, inpatient, specialist outpatient and 24-hour emergency 
services for the population in the central and western parts of 
Singapore [116]. The 9 primary care clinics, also known as polyclinics, 
are a government primary care provider organisation with a service 
load of 3.7 million visits in 2010, which accounted for 60% of the entire
public sector [115]. Data was drawn from the NHG CDMS, which was
commissioned in 2007 with the aim to build a registry that helps to 
provide seamless care for patients with chronic diseases and to 
facilitate greater efficiency in outcome measurement. The system links 
administrative and key clinical data of patients with stroke within the 
NHG healthcare cluster, including physician visits, medication and 
laboratory test records [116, 141].
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Patient selection
The ICD-9-CM was used to identify patients with stroke. The patients 
were selected if found to have both diagnostic codes between 430-436 
as a primary or secondary diagnosis, in addition to having pharmacy
medication records and laboratory data available in the CDMS.
Frequently encountered stroke complications and comorbidities were 
also identified using ICD-9-CM codes, while medications and 
laboratory data were extracted based on inpatient and outpatient 
encounters registered with the CDMS. 
This study included patients who were at least 21 years of age and had 
an ICD-9-CM code between 430 and 436 (SAH=430; IS=431, 433, 
434; ICH=432; TIA=435; unspecified=436) or attended treatment for 
stroke in any NHG institution. Patients with stroke were stratified by
stroke types: IS, SAH, ICH, and TIA. Patients were also further divided 
into two groups (acute and prevalent). They were considered acute if 
they had a stroke onset in the year 2011 and prevalent if they had a 
stroke onset between 2006-2010. To determine the date of stroke 
onset, only the first hospitalisation for each acute patient was included, 
and when prevalent patients presented with multiple strokes during the 
study’s time frame, the most recent stroke type other than TIA was 
selected for analysis. In addition, patients needed to have at least one 
record in the CDMS in the year 2012 if acute and the year 2013 if 
prevalent to ensure survival post stroke. Patients with strokes other 
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than IS, SAH, ICH and TIA were excluded. To ensure a representative 
sample of different types of stroke, 150 IS patients, 50 SAH patients, 
100 ICH patients, and 50 TIA patients were randomly selected for 
acute and prevalent groups, giving a total of 700 patients selected for 
analysis. 
Resource use and cost estimation
Direct stroke-related costs were classified by the type of service, which 
included inpatient hospitalisation, A&E and ambulatory outpatient care 
(physician visits, laboratory tests and medications). The total medical 
costs were estimated using the total before-subsidy charges, which is
the total medical bill before any deductions that result from government 
subsidies and insurance claims. Discounting was not required because 
only one-year cost was estimated. Costs estimated were for a period of 
one year; all resources utilised for the year 2012 were reported in 
Singapore currency (S$) using year 2012 prices.
Costs of inpatient care and A&E services were estimated by the total 
charge, which was determined by the length of stay and the resources 
used. A&E visits that resulted in hospitalisation were included as 
inpatient costs. Physician visits included visits to primary care clinics 
(polyclinics) and SOC (hospitals). The standardised rate at all NHG 
primary care clinics and hospitals was used as the unit costs for 
physician visits. Costs were estimated by multiplying the number of 
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physician visits by the unit cost of a visit. Costs of medications and 
laboratory tests were estimated via the same method. Since there is no 
stroke-specific medications or laboratory tests, the most commonly 
prescribed medications and ordered laboratory tests for stroke patients 
were included in the cost estimation. All unit costs were provided by the 
NHG and were in Singapore dollars. Direct non-medical costs, such as 
out-of-pocket expenses and indirect or productivity costs for loss of 
work were not included in this study.  
Statistical analysis
Logarithmic transformation of the cost data was performed since 
healthcare cost data are often positively skewed due to a relatively 
small proportion of patients incurring extremely high costs [142, 143]. 
Descriptive statistics (frequency, percentage, mean, median, standard 
deviation and 90th percentile) were used to present costs and patients’ 
demographics. Multiple linear regression analyses were performed to 
determine the predictors of the total costs. All statistical analyses were 
performed using SPSS version 22.0 (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics  
Chapter 4. Direct medical cost of stroke in Singapore                                        Ng, CS
73
A total of 8,230 (2,144 acute; 6,086 prevalent) stroke patients in the 
NHG CDMS (2006-2012) were identified as stroke patients. After 
random sampling, 700 patients were included in the analyses, of which 
half were acute and half prevalent. The socio-demographic profile of 
the patients is shown in Table 4.1. The overall patient sample was 
equally distributed between the two genders (55.1% male), and the 
mean (±SD) age was 62.7 ± 13.5 years. The mean (±SD) length of 
post-stroke period was 1.7 ± 1.5 years and most study patients were 
Chinese (83.1%). Of the 350 prevalent patients, only 12.3% had one or 
more inpatient visits compared to 93.1% in the acute group. Urinary 
tract infection (UTI) (19.0%) and pneumonia (6.0%) were the most 
common stroke complications among the cohort. Only 9 (1.3%) 
patients had retinopathy, while dyslipidaemia (85.6%), hypertension 
(76.6%) and DM (32.1%) were common comorbidities. 
Among the four types of stroke, men comprised slightly more than half 
of the patients in the IS (60.0%), ICH (62.0%) and TIA (55.0%) groups, 
while only 27% of the patients were male in the SAH sample. On 
average, patients with SAH tended to be younger than those with the 
other types of stroke and the majority of the patients were Chinese in 
all stroke groups. The mean length of post-stroke period was also 
similar amongst the four stroke types. Similar to the overall patient 
sample, patients with different stroke types had UTI and pneumonia as 
common complications, while dyslipidaemia, hypertension and DM 
were common comorbidities. 
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Table 4.1: Socio-demographic and clinical characteristics of patients with stroke, CDMS 2006-2012
Characteristic n (%)* or mean ± standard deviation
Overall (n=700) IS (n=300) SAH (n=100) ICH (n=200) TIA (n=100)
Age (years) 62.7 ± 13.5 65.7 ± 13.6 55.4 ± 13.9 61.7 ± 11.9 62.8 ± 13.1
Gender
Male 386 ( 55.1 ) 180 ( 60.0 ) 27 ( 27.0 ) 124 ( 62.0 ) 55 ( 55.0 )
Female 314 ( 44.9 ) 120 ( 40.0 ) 73 ( 73.0 ) 76 ( 38.0 ) 45 ( 45.0 )
Race 
Chinese 582 ( 83.1 ) 239 ( 79.7 ) 82 ( 82.0 ) 178 ( 89.0 ) 83 ( 83.0 )
Malay 65 ( 9.3 ) 36 ( 12.0 ) 11 ( 11.0 ) 9 ( 4.5 ) 9 ( 9.0 )
Indian 35 ( 5.0 ) 18 ( 6.0 ) 4 ( 4.0 ) 8 ( 4.0 ) 5 ( 5.0 )
Others 18 ( 2.6 ) 7 ( 2.3 ) 3 ( 3.0 ) 5 ( 2.5 ) 3 ( 3.0 )
Post-stroke period (years) 1.7 ± 1.5 1.6 ± 1.4 1.7 ± 1.5 1.7 ± 1.5 1.7 ± 1.5
Length of stay (days)
Acute (n=350) 27.4 ± 39.7 23.0 ± 30.7 39.3 ± 44.1 39.0 ± 51.4 4.9 ± 7.8
Prevalent (n=350) 1.9 ± 9.4 2.3 ± 9.2 1.0 ± 3.1 2.5 ± 13.3 0.7 ± 3.0
≥ 1 inpatient visit 
Acute (n=350) 326 ( 93.1 ) 141 ( 47.0 ) 50 ( 50.0 ) 99 ( 49.5 ) 36 ( 36.0 )
Prevalent (n=350) 43 ( 12.3 ) 18 ( 6.0 ) 7 ( 7.0 ) 14 ( 7.0 ) 4 ( 4.0 )
Stroke complications
Urinary tract infection 133 ( 19.0 ) 48 ( 16.0 ) 35 ( 35.0 ) 44 ( 22.0 ) 6 ( 6.0 )
Pneumonia 42 ( 6.0 ) 15 ( 5.0 ) 9 ( 9.0 ) 16 ( 8.0 ) 2 ( 2.0 )
Acute myocardial infarction 17 ( 2.4 ) 6 ( 2.0 ) 0 ( 0.0 ) 5 ( 2.5 ) 6 ( 6.0 )
Deep vein thrombosis 8 ( 1.1 ) 3 ( 1.0 ) 2 ( 2.0 ) 2 ( 1.0 ) 1 ( 1.0 )
Gastrointestinal tract bleeding 8 ( 1.1 ) 4 ( 1.3 ) 1 ( 1.0 ) 3 ( 1.5 ) 0 ( 0.0 )
Decubitus ulcer 3 ( 0.4 ) 1 ( 0.3 ) 0 ( 0.0 ) 2 ( 1.0 ) 0 ( 0.0 )
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Table 4.1: Socio-demographic and clinical characteristics of patients with stroke, CDMS 2006-2012 (continued)
Characteristic n (%)* or mean ± standard deviation
Overall (n=700) IS (n=300) SAH (n=100) ICH (n=200) TIA (n=100)
Stroke comorbidities
Dyslipidaemia 599 ( 85.6 ) 291 ( 97.0 ) 56 ( 56.0 ) 155 ( 77.5 ) 97 ( 97.0 )
Hypertension 536 ( 76.6 ) 247 ( 82.3 ) 41 ( 41.0 ) 174 ( 87.0 ) 74 ( 74.0 )
Diabetes mellitus 225 ( 32.1 ) 120 ( 40.0 ) 11 ( 11.0 ) 60 ( 30.0 ) 34 ( 34.0 )
Chronic kidney disease 102 ( 14.6 ) 56 ( 18.7 ) 4 ( 4.0 ) 27 ( 13.5 ) 15 ( 15.0 )
Ischaemic heart disease 99 ( 14.1 ) 48 ( 16.0 ) 5 ( 5.0 ) 24 ( 12.0 ) 22 ( 22.0 )
Atrial fibrillation 68 ( 9.7 ) 44 ( 14.7 ) 3 ( 3.0 ) 13 ( 6.5 ) 8 ( 8.0 )
Heart failure 38 ( 5.4 ) 19 ( 6.3 ) 3 ( 3.0 ) 12 ( 6.0 ) 4 ( 4.0 )
Peripheral vascular disease 27 ( 3.9 ) 17 ( 5.7 ) 1 ( 1.0 ) 4 ( 2.0 ) 5 ( 5.0 )
Retinopathy 9 ( 1.3 ) 7 ( 2.3 ) 0 ( 0.0 ) 2 ( 1.0 ) 0 ( 0.0 )
* Percentages may not add up to 100% due to rounding
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Annual costs of stroke
The mean annual direct cost of stroke was estimated to be S$12,473.7 
(US$1.0 = S$1.2 as of 31 December 2012) [73], of which S$11,672.5 
was for inpatient services, S$188.7 for A&E services and S$612.5 for 
outpatient services (Table 4.2). Of the total healthcare expenditure, the 
main cost driver was inpatient costs (93.6%), while A&E services (1.5%) 
were only a small portion of the total costs. The major source of costs 
for outpatient services was physician visits, which accounted for 4.9% 
of the total healthcare expenditure and 75.0% of total outpatient 
expenditure.
Patients with SAH (S$22,990.9) were the most costly on average, 
followed by patients with ICH (S$16,600.6), IS (S$9,138.5) and TIA 
(S$3,708.5). The mean costs were 4.1 times higher than median cost 
estimates for patients with SAH and 4.4 times for patients with ICH, 
demonstrating that a minority of patients with extremely high costs had 
a substantial influence on the mean estimates. The mean costs for 
patients with IS and TIA were less influenced by outliers. Inpatient 
costs were higher in the IS (S$8,303.5), SAH (S$22,464.9) and ICH 
(S$15,702.3) groups when compared to the TIA group (S$2,927.9), 
indicating a higher resource consumption in those groups. Conversely, 
patients with TIA had a higher proportion of resource consumption for 
outpatient services than the other stroke groups. Outpatient costs were 
consistent across the four stroke groups, with physician services 
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accounting for the majority of total expenditure, followed by laboratory 
tests and medications (Table 4.2).
Healthcare expenditure across all services was substantially higher in 
acute patients than prevalent patients. The mean annual costs were 
S$22,721.3 (acute) and S$2,226.2 (prevalent), of which 95.5% and 
73.5%, respectively, were accounted for by inpatient services. 
Outpatient services were more utilised in the prevalent arm, which is 
evident when comparing the proportion of outpatient costs to the total 
costs in each group. Although the proportion of outpatient costs in 
physician services, laboratory tests and medications were similar in 
both groups, the mean total physician visit cost was higher in acute 
patients (Table 4.3). 
Predictors of total costs
Cost predictors were investigated using multiple linear regression with 
log transformation. A greater total cost of stroke was significantly 
associated with stroke type (IS, SAH and ICH), shorter post-stroke 
period, more than one stroke complications and a greater number of 
comorbidities. This model explained 61.0% of the variance in costs 
(Table 4.4). Compared with patients with TIA, the mean annual total 
cost of those with IS was 18.2% higher (p=0.005), while the increase in 
the total costs of patients with SAH (41.0%, p<0.001) and ICH (29.2%, 
p<0.001) was even greater. Age, gender, and race were not 
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independently associated with the total cost. 
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Table 4.2: Direct medical costs incurred by stroke type at different site of care










Cost (S$) 2,491,036.8 2,246,490.7 3,140,451.2 292,791.0 8,170,769.7
Percentage of total cost (%)* 90.9 97.7 94.6 79.0 93.6
Mean 8,303.5 22,464.9 15,702.3 2,927.9 11,672.5
SD ± 15,742.1 ± 34,614.8 ± 43,657.7 ± 7,228.2 ± 29,374.2
Median 2,286.0 5,324.4 2,549.4 1,232.7 2,013.9
90th percentile 23,719.2 59,640.1 40,987.3 4,508.4 33,877.7
Accident & Emergency 
Cost (S$) 55,553.2 12,892.3 41,599.3 22,012.6 132,057.4
Percentage of total cost (%)* 2.0 0.6 1.3 5.9 1.5
Mean 185.2 128.9 208.0 220.1 188.7
SD ± 284.3 ± 211.8 ± 302.5 ± 375.5 ± 296.2
Median 58.7 0.0 111.0 128.0 0.0
90th percentile 538.7 394.9 633.7 588.2 523.5
Outpatient
Cost (S$) 194,960.1 39,702.4 138,061.6 56,043.7 428,767.8
Percentage of total cost (%)* 7.1 1.7 4.2 15.1 4.9
Mean 649.9 397.0 690.3 560.4 612.5
SD ± 620.2 ± 534.7 ± 1,396.6 ± 439.9 ± 892.8
Median 482.7 225.3 383.3 485.7 415.8
90th percentile 1,469.4 914.0 1,336.8 1,227.9 1,255.0
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Table 4.2: Direct medical costs incurred by stroke type at different site of care (continued)










Cost (S$) 134,753.1 35,213.8 115,355.9 38,726.9 324,049.7
Percentage of total outpatient cost (%)* 69.1 88.7 83.6 69.1 75.6
Mean 449.2 352.1 576.8 387.3 462.9
SD ± 443.4 ± 519.8 ± 1,357.1 ± 300.6 ± 816.0
Median 306.7 209.3 277.8 315.0 281.6
90th percentile 1,013.8 670.7 1,064.4 822.5 912.0
Outpatient laboratory tests
Cost (S$) 41,823.7 2,816.9 15,934.3 11,271.0 71,845.9
Percentage of total outpatient cost (%)* 21.5 7.1 11.5 20.1 16.8
Mean 139.4 28.2 79.7 112.7 102.6
SD ± 196.5 ± 57.5 ± 107.5 ± 135.0 ± 156.2
Median 88.6 0.0 59.3 81.8 71.7
90th percentile 355.3 123.1 193.7 277.5 245.8
Outpatient medications
Cost (S$) 18,383.3 1,671.8 6,771.4 6,045.8 32,872.2
Percentage of total outpatient cost (%) 9.4 4.2 4.9 10.8 7.7
Mean 61.3 16.7 33.9 60.5 47.0
SD ± 101.6 ± 60.6 ± 84.7 ± 112.3 ± 95.1
Median 29.5 0.0 5.9 27.0 14.7
90th percentile 154.4 6,771.4 80.7 126.6 122.1
TOTAL COST
Cost (S$) 2,741,550.1 2,299,085.4 3,320,112.1 370,847.4 8,731,594.9
Mean 9,138.5 22,990.9 16,600.6 3,708.5 12,473.7
SD ± 16,095.6 ± 34,748.5 ± 43,755.2 ± 7,479.4 ± 29,517.2
Median 3,109.3 5,601.7 3,801.1 1,888.3 2,929.2
90th percentile 26,213.1 60,193.7 41,368.2 5,619.3 35,102.1
* Percentages may not add up to 100% due to rounding
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Table 4.3: Direct medical costs incurred by patient type at different site of care




Cost (S$) 7,598,109.3 572,660.5
Percentage of total cost (%)* 95.5 73.5
Mean 21,708.9 1,636.2
SD ± 38,419.7 ± 7,075.2
Median 9,118.6 0.0
90th percentile 50,220.4 3,280.0
Accident & Emergency 
Cost (S$) 108,898.0 23,159.4
Percentage of total cost (%)* 1.4 3.0
Mean 311.1 66.2
SD ± 335.4 ± 182.0
Median 245.2 0.0
90th percentile 683.7 273.0
Outpatient
Cost (S$) 245,433.6 183,334.2
Percentage of total cost (%)* 3.1 23.5
Mean 701.2 523.8
SD ± 813.0 ± 959.1
Median 477.3 385.7
90th percentile 1,522.1 899.9
Outpatient physician visits
Cost (S$) 190,299.0 133,750.7
Percentage of total outpatient cost (%)* 77.5 73.0
Mean 543.7 382.1
SD ± 696.1 ± 914.4
Median 340.9 234.6
90th percentile 1,237.5 624.9
Outpatient laboratory tests
Cost (S$) 39,109.3 32,736.6
Percentage of total outpatient cost (%)* 15.9 17.9
Mean 111.7 93.5
SD ± 187.1 ± 117.0
Median 34.4 82.9
90th percentile 330.1 193.9
Outpatient medications
Cost (S$) 16,025.4 16,846.8
Percentage of total outpatient cost (%)* 6.5 9.2
Mean 45.8 48.1
SD ± 105.4 ± 83.8
Median 10.3 18.8
90th percentile 113.6 126.6
TOTAL COST
Cost (S$) 7,952,440.9 779,154.1
Mean 22,721.3 2,226.2
SD ± 38,490.9 ± 7,269.5
Median 9,938.0 444.6
90th percentile 53,080.3 4,925.8
* Percentages may not add up to 100% due to rounding
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Table 4.4: Factors influencing the total annual cost of stroke (n=700)
Characteristic β-coefficient 95% CI P value
Individual level factors
Age (per year increase) 0.001 -0.003 0.004 0.634
Gender
Male (reference)
Female -0.045 -0.133 0.042 0.307
Race 
Chinese (reference)
Malay 0.083 -0.063 0.228 0.265
Indian 0.013 -0.178 0.204 0.891
Others 0.117 -0.147 0.380 0.385
Stroke type
TIA (reference)
IS 0.182 0.055 0.308 0.005
SAH 0.410 0.243 0.577 <0.001
ICH 0.292 0.157 0.427 <0.001
Post-stroke period
Acute <1 year (reference)
Prevalent 1 to 3 years -1.230 -1.326 -1.133 <0.001
Prevalent >3 years -1.411 -1.519 -1.303 <0.001
Stroke complications 
None (reference)
1 complication 0.103 -0.005 0.211 0.061
>1 complications 0.207 0.004 0.410 0.045
Stroke comorbidities
Number of comorbidities (per 1 increase) 0.055 0.022 0.089 0.001
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Discussion
This prevalence-based COI study involved a large captive population 
with stroke in Singapore. The analysis was based on cost,
administrative and clinical data retrieved from the NHG disease registry 
from 2006-2012. This is the first study to provide estimates of the 
distribution of costs among the different stroke types as well as costs 
among acute and prevalent patients in both inpatient and ambulatory 
care in Singapore. 
The cost per patient estimate in the present study was S$12,473.7 
(US$10,190.3), and this appears to be higher than those reported in 
other Asian countries. Two studies in Korea reported an estimate of 
approximately KRW$8 million per patient [144, 145], while in China it 
costs CNY$30,438.3 per patient for the management of stroke [143]. 
Notably, direct medical costs reported in the American [146] and 
European [147, 148] continents were much higher than those 
estimated in this study. The comparison of mean total cost with other 
studies was further hindered by the estimation of only first year (acute) 
or hospitalisation costs and the limited number of stroke types included 
in most studies. 
Despite the differences in total costs estimated, inpatient costs remain 
the main cost driver, which is consistent with previous stroke COI 
studies [58, 143, 149]. The high costs in inpatient services are often 
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strongly correlated to LOS [121, 122], where a higher LOS results in 
higher costs. Previous studies [150, 151] have also reported that 
having complications was associated with a significant increase in the 
LOS. With the many complications accompanying a stroke, it is 
inevitable that inpatient care dominates the total healthcare 
expenditure. This fact underlines the need for effective preventative 
measures and careful treatment of these complications. Furthermore, 
early mobilisation and careful monitoring of clinical parameters seem to 
be beneficial as well [152, 153]. In terms of outpatient costs, physician 
services contributed to the bulk of the total expenditure, which is 
understandable since the growth in the number of physicians and 
specialists in outpatient care has risen over the years to meet patient 
demands, resulting in an increase in outpatient physician visits. One 
study [154] proposed increasing the case load of physicians, which 
provides opportunities for physicians to develop cost-effective as well 
as technically effective medical treatment skills to deal with the high 
demands. This may also make them more savvy in coordinating the 
various treatment elements and discharge planning, leading to a 
reduction in costs related to care content. As outpatient physicians are 
central to the healthcare system, efforts to contain physician spending 
will have positive effects on all healthcare services.
As in previous studies, patients with SAH were younger, have lower 
outpatient costs and higher overall costs compared with other 
cerebrovascular diseases [155-158]. This young age could lead to 
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greater lifetime costs, due to long-term management of the disease 
and loss of productivity costs [57, 159, 160], which raises a concern for 
the national economy because of the diminishing workforce. On the 
other hand, IS were more common in the elderly, in particular, in 
individuals above the age of 65 [161]. Due to the non-disabling nature 
of TIA, these patients are more commonly managed as outpatients 
than inpatients [162] and results in lower overall healthcare costs, 
which was further validated in the regression analysis. The general 
consensus was that haemorrhagic strokes on the whole were more
costly than IS and TIA [149, 163, 164], given the frequent need for 
surgery and intensive monitoring with high levels of subsequent 
morbidity [146, 165, 166].
Cost of stroke within the first year of occurrence is concerning, with
healthcare use being substantially higher when compared to prevalent 
patients [59, 147, 167]. This vast disparity was mainly due to inpatient 
costs dominating the burden for acute cases with high ward charges 
and diagnostic tests. The severity of the disease coupled with multiple 
follow-ups at outpatient clinics could also be possible explanations 
[122, 147]. The present study’s cost estimates for the acute phase are 
noticeably much higher than those obtained by three [137, 168, 169]
previous studies done in Singapore. Chow et al [168] estimated an 
average cost of S$6,783, while S$7,547 was reported by 
Venketasubramanian et al [137] and S$2,410.8 by Saxena et al [169]. 
However, it should be noted that these earlier studies only estimated 
Chapter 4. Direct medical cost of stroke in Singapore                                        Ng, CS
86
hospitalisation costs. Furthermore, Chow et al included only patients 
with IS, while Saxena et al estimated costs in a community hospital 
setting. The heavy inpatient focus of hospitals is not cost-effective for 
the management of chronic diseases. Data for diseases such as 
asthma and congestive heart failure [170, 171] clearly indicate that cost 
savings come from what happens over the long term outside of 
hospitals to prevent acute episodes from occurring [172], and much of 
these savings may have been the result of empiric identification of 
barriers to efficient diagnosis and management as well as more 
aggressive discharge planning. 
The results of regression analyses generally confirmed what might 
have been expected based on epidemiologic evidence in the literature. 
That is, complications and comorbidities tend to increase the cost of 
care. A study by O’Brien and colleagues [173] found that complications 
that are initially relatively low in cost could progress to become more 
costly in the advanced stages due to higher resource consumption. For 
example, stroke patients with multiple complications and/or 
comorbidities would naturally require medications for each condition,
further driving up the healthcare cost of stroke survivors [174]. As such, 
it may be that efforts to curb stroke complications would not only result 
in a decrease in medication costs but also decreased costs at all sites 
of care (inpatient and outpatient), due to the decline in LOS as well as 
number of follow-ups. Thus, decreasing the rate of people developing 
Chapter 4. Direct medical cost of stroke in Singapore                                        Ng, CS
87
complications and/or comorbidities through patient-targeted disease-
management could be beneficial in reducing overall healthcare costs.
This study is not without limitations. First, data was drawn from a 
healthcare database and, as such, relied on the accuracy and 
completeness of the records. However, the NHG CDMS has been used 
in several studies and is recognised as providing well-validated and 
comprehensive data [115, 134]. The integration of both administrative 
and clinical data allows a detailed characterisation of the patient at the 
index date and was also useful in running prediction models. Second, 
patients with stroke other than IS, SAH, ICH and TIA, along with 
indirect and intangible costs and out-of-pocket expenses were not 
examined in this study.  These limits in scope have likely 
underestimated the true cost of stroke. In addition, due to the lack of 
data, stroke severity, which is an important predictor of costs, was 
omitted from the analysis. Third, the study population was limited to the 
public healthcare sector in Singapore. Nevertheless, the strength of 
this prevalence-based COI study lies in that all cases of stroke are 
included for a specified year, which allows for a cross-section of 
patients in various stages of the illness.
Conclusion
This study provides a comprehensive cost analysis for the stroke 
population in Singapore. The results indicate that stroke type, length of 
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post-stroke period as well as stroke complications and comorbidities 
are significant determinants of the total costs. With an aging 
population, the prevalence of stroke in Singapore will continue to grow 
in the years to come, resulting in a heavy burden on health budgets. 
Hence, it is important to understand what drives costs in order to 
further underscore the need for effective preventive therapies, timely 
critical care and well-designed rehabilitation programs to contain 
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Chapter 5 Cost of Osteoporotic Fractures in Singapore
Introduction
Osteoporosis is a bone condition closely related to advancing age that 
is characterised by reduced bone mass and microarchitectural 
deterioration of bone tissue with a consequent increase in bone fragility 
and susceptibility to fractures [175-177]. It is considered a serious 
public health concern, with an estimated 200 million people worldwide 
suffering from this disease [178]. Osteoporosis-related fractures are 
associated with a high degree of morbidity and mortality [179]. The 
average lifetime risk of an elderly over the age of 50 to experience 
osteoporotic fracture has been estimated at 40-50% for women and 13-
22% for men [180]. In 2000, 9 million osteoporotic fractures occurred 
worldwide, including 1.6 million hip fractures, 1.7 million forearm
fractures, and 1.4 million clinical vertebral fractures [38, 39]. In 
Singapore, hip fracture incidence rates have risen 1.5-fold for men and 
5-fold for women since the 1960s. The age-adjusted hip fractures rates 
among women over the age of 50 years are about 402 per 100,000 
females and this figure is now among the highest in Asia [47-49].
Osteoporotic fractures are a chronic condition and one of the most 
common causes of disability, incurring substantial costs in many 
regions of the world. The annual costs of all osteoporotic fractures 
have been variously estimated to be US$20 billion in the United States 
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[60], €30 billion in the European Union [61] and AU$1.8 billion in 
Australia [62]. A study conducted in Singapore in 2001 estimated the 
mean hospitalisation cost for patients with hip fractures treated 
surgically to be S$10,515 [181].
By 2050, the percentage of the population aged 60 years and above in 
Singapore is projected to increase to 38% [182]. With an aging 
population, the number of hip fractures per year is projected to 
increase from 1,300 in 1998 to 9,000 by 2050 [48]. Despite the large 
number of people affected by osteoporosis, no previous study in 
Singapore has compared the costs of patients with acute to those with 
prevalent osteoporotic fractures or examined these groups indirect 
costs in Singapore. It is timely to estimate current various costs of 
osteoporotic fractures in the local context so as to develop policies, 
allocate resources appropriately and justify intervention programs 
resulting in potential financial savings.
The present study aims to identify the total direct and indirect costs of 
osteoporotic fractures in Singapore from both the hospital’s and 
patient’s perspectives, including cost comparisons between patients 
with acute and those with prevalent osteoporotic fractures.




This study adopted a prevalence-based approach, employing a bottom-
up methodology to estimate different cost components. The prevalence 
approach can yield more precise estimates because it ascertains the 
current economic burden of a disease rather than projected ones [114]. 
The perspective for this study was that of the National University 
Hospital (NUH) and patients with osteoporotic fractures.  
Data collection
A prospective observational study of patients with osteoporotic 
fractures was conducted from late July 2013 to January 31, 2014 over 
a 6-month period. The NUH is a 997-bed public tertiary hospital serving 
more than 670,000 outpatients and 59,000 inpatients in 2010 [183].
Data regarding resource use was collected using interviewer-
administered questionnaires at baseline (i.e. the date of interview) and 
at a 3-month follow-up to minimise recall bias. The interviews were 
conducted at the department of orthopaedics of NUH, which includes 
inpatient wards, outpatient specialist clinics, the A&E department and 
other relevant clinics (i.e. the radiological department). The 
questionnaires (See Appendix I and II) used were adapted from 
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existing instruments developed by the collaborating NUH 
rheumatologist and a corresponding author of a COI study conducted 
in Singapore. Either the English or Chinese version of the 
questionnaire was administered, depending on the patient’s
preference. At baseline, patients’ demographics, clinical characteristics 
and resources used for that particular visit were obtained. Patients 
were then asked to take note week by week of all contacts, receipts or 
bills they had with or from the healthcare system for the next 3-months. 
At the 3-month follow-up, information on resource use since the last 
visit was collected. Patient-reported information at baseline and follow-
ups were primarily collected via interviews in connection with the 
hospital visits related to the fracture event. If the interview could not be 
conducted in relation to the hospital visit, the information were collected 
via a telephone interview. In circumstances where the patient was 
unable to respond to the questions accurately, the questionnaires were 
given to a “proxy-responder” (i.e. a person in close contact with the 
patient). 
Patient selection
To be included in the study, patients were required to have a bone 
mineral density (BMD) scan or relevant X-ray examinations to ensure 
that their fractures were low-trauma (i.e. sustained from standing height 
or less) and fulfill the following criteria: (1) above 50 years of age, (2) 
vertebral column, hip, humerus, wrist or other fragility fracture (except 
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skull, below ankle and distal to the wrist) and (3) able to ambulate with 
or without aid before fall (i.e. not wheelchair or bed bound). Eligible 
patients were identified through visits to the department of 
orthopaedics (inpatient ward and outpatient specialist clinics), A&E 
department or were identified by the case finding approach at other 
relevant clinics. This was an Institutional Review Board-approved study 
and written informed consent was obtained for each patient. 
The consequences related to fractures can be divided into an acute 
incident phase and a post-prevalent fracture phase. Patients were 
categorised as being in the acute phase if the fracture occurring ≤ 4 
weeks prior to the interview was their first fracture, while patients who 
had their present fracture for over one year were considered prevalent. 
Patients with a pathological fracture due to metastasis or patients 
seeking care for multiple fractures simultaneously were excluded. 
Patients with apparent cognitive impairment that would have prevented 
them from answering the survey questions accurately were also 
excluded.
Estimation of direct medical costs
Direct medical cost was classified by the type of service, which 
included inpatient hospitalisation, A&E and ambulatory outpatient care 
(physician visits, laboratory tests, rehabilitations and medications). The 
total costs were estimated using the total before-subsidy and after-
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subsidy charges, which is the total medical bill before and after any 
deductions that result from general government subsidies. Subsidies 
from government programs such as Medisave, Medifund, MediShield 
and ElderShield as well as any private insurance claims, individual or 
employer-provided were not taken into consideration. 
Costs of inpatient care and A&E services were estimated by the total 
charge, which was determined by the length of stay and the resources 
used. A&E visits that resulted in hospitalisation were included as 
inpatient costs. Physician visits included visits to primary care clinics 
(polyclinics) and SOC (hospitals) and were estimated based on the 
receipts or bills provided by the patient. Laboratory tests such as X-
rays, magnetic resonance imaging (MRI), BMD or blood tests and 
rehabilitation services were estimated via the same method. Physician 
visits that included laboratory tests that were done in tandem during the 
same visit were included as physician visit costs because receipts were 
generated based on a pre-programmed government subsidy deduction 
of the total charge for that visit. Rehabilitation costs that required 
admission to the community hospital were also estimated by the total 
charge. A standardised rate obtained from the pharmacy was used to 
calculate unit prices for osteoporosis-related prescription medications 
(Table 5.1). Costs were estimated by multiplying the number of 
medications prescribed by the unit cost of each medication. Non-
prescription medications such as vitamins or supplements are not 
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eligible for government subsidies and were estimated based on 
receipts provided by the patient.
Table 5.1: Osteoporosis-related prescription medications 
Drug Brand name
Alendronate Fosamax 10 mg®
Fosamax 70 mg®
Denosumab Prolia 60 mg®
Risedronate Actonel 35 mg®
Strontium Ranelate Protelos 2 g®
Teriparatide Forteo 20 mcg®
Zoledronate Aclasta 5 mg®
Zometa 5 mg®
Calcitonin (nasal spray) Calcitonin Novartis Nasal Spray®
Calcium carbonate                                 
(450 mg) + Vit D (200 IU)
Non-specific
Vitamin D3 (1,000 / 5,000 IU) Lynae®
Ergocalciferol                                      
(1.25 mg) + Vit D (50,000 IU)
Non-specific
Estimation of direct non-medical costs
Direct non-medical costs consisted of transportation, healthcare and 
community services as well as special equipment and home/car 
modifications. Healthcare and community services included but were 
not limited to massage therapy, acupuncture, traditional Chinese 
medicine (TCM), meal delivery, domestic helpers and community 
private nursing. Special equipment and home/car modifications 
included but were not limited to bathroom equipment (commode, 
handle bars), bedroom room equipment (rope ladder, mattress), 
crutches, wheelchairs, home modifications (ramps, steps alteration) 
and car modifications (seat alteration, steering devices). 
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Direct non-medical costs are not eligible for government subsidies and 
were estimated as total charge based on the receipts provided by the 
patient. Transportation via personal car was calculated based on the 
distance travelled multiplied by the unit cost of petrol (S$0.45/km) 
[184]. The use of mass rapid transit (MRT), bus or taxi were estimated 
using a web-based calculator [185]. The cost for a domestic helper was 
estimated using a conservative rate of 50% of their total salary per 
month, with the assumption that the helper would not be spending a 
100% of his or her time caring for the patient. 
Estimation of indirect costs
Indirect costs were estimated using the human capital approach rather 
than the friction-cost method because the former is grounded in 
neoclassical economic theory while the latter is not [186]. Moreover, 
Singapore’s unemployment rate in 2013 remained low, and it is only in 
the case of labour market imperfections or periods of high 
unemployment that the friction-cost approach should be considered 
[61]. Productivity loss due to absence from work and costs of informal 
(unpaid) care provided by family members and/or other persons were 
included in the indirect cost estimation. Working patients were asked 
their current occupation and to estimate how many days and/or hours 
of productivity had been lost because of their fracture. As individual 
hourly wage rates were not available, monthly occupational wages 
obtained from the Ministry of Manpower (MOM) [187] were used to 
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derive hourly earnings with the assumption that a full-time worker is 
employed 5 days per week, 8 hours per day. Absenteeism was thus 
calculated by multiplying the number of hours of absence from work 
with the hourly rates. The occupation “housekeeper” was used to 
calculate the hourly earnings of patients who were homemakers. 
Informal care was estimated using the same method above. Patients 
were asked the occupation of their primary caregiver and to estimate 
the hours of care provided by them. For caregivers who were 
employed, the occupational wages from MOM was used and multiplied 
by the number of hours spent on caring for the patient. The occupation 
“housekeeper” was used for caregivers who were homemakers or have 
retired. 
Statistical analysis
Descriptive statistics (frequency, percentage, mean, median, standard 
deviation and 90th percentile) were used to present costs and patients’ 
demographics. Before-subsidy charges were used for cost estimation 
when taking the hospital’s perspective, which included only direct 
medical costs, while after-subsidy charges were used for cost 
estimation when taking the patient’s perspective, which included direct 
medical costs as well as direct non-medical costs and indirect costs. 
Only osteoporotic fracture-related costs were included. Discounting 
was not required because all costs estimated were for a 3-month 
period and were reported in Singapore currency (S$) using year 2013 
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prices. All statistical analyses were performed using SPSS version 22.0
(SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics  
A total of 104 eligible patients were approached: 67 (16 acute; 51 
prevalent) agreed to participate in this study, giving a response rate of 
64.4%. The socio-demographic profile of the patients is shown in Table 
5.2. A majority of patients were female (89.6%), Chinese (88.1%), 
married (59.7%), non-smokers (95.5%), retired (70.1%), and living with 
their spouse, children or relatives (92.5%). The mean (±SD) age was 
73.7 ± 10.8 years and mean (±SD) duration of fracture was 2.7 ± 2.6 
years. Approximately one-third of the patients did not attend school 
(38.8%) and had a monthly household income between S$1,000 to 
S$2,999 (34.3%). The number of patients who had a spouse (34.3%) 
serving as their primary caregivers was similar to the number who had 
other help such as a domestic helper (35.8%). More than half of the 
patients declined using private insurance (88.1%) or government 
programs (77.6%) to file claims for the expenses related to their 
fracture, and only a handful received money from Medifund (4.5%) and 
health insurance from their employer (3.0%). The most common 
fractures identified were those of the vertebral column (43.3%) and hip 
(34.3%), and 88.1% of patients were experiencing their first fracture. 
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Table 5.2: Socio-demographic and clinical characteristics of patients 
with osteoporotic fractures 2013 (n=67)
Characteristic




Age (years) 73.7 ± 10.8
Gender
Female 60 ( 89.6 )
Male 7 ( 10.4 )
Race
Chinese 59 ( 88.1 )
Indian 4 ( 6.0 )
Malay 3 ( 4.5 )
Others 1 ( 1.5 )
Marital status
Married 40 ( 59.7 )
Widow 24 ( 35.8 )
Single 3 ( 4.5 )
Highest level of education
No school 26 ( 38.8 )
Primary 18 ( 26.9 )
Secondary 14 ( 20.9 )
Junior college / polytechnic 4 ( 6.0 )
University 5 ( 7.5 )
Monthly household income (S$)
No income 12 ( 17.9 )
<1,000 4 ( 6.0 )
1,000-2,999 23 ( 34.3 )
3,000-4,999 10 ( 14.9 )
>5,000 18 ( 26.9 )
Smoking status
Non-smoker 64 ( 95.5 )
Smoker 3 ( 4.5 )
Employment status
Retired 47 ( 70.1 )
Employed 6 ( 9.0 )
Unemployed 1 ( 1.5 )
Other 13 ( 19.4 )
Current living arrangement
Live with spouse / children / relatives 62 ( 92.5 )
Live alone 2 ( 3.0 )
Other 3 ( 4.5 )
Primary caregiver
Spouse / partner 23 ( 34.3 )
Daughter / son 20 ( 29.9 )
Other 24 ( 35.8 )
Receive money from Medifund
No 64 ( 95.5 )
Yes 3 ( 4.5 )
Plan to use government schemes1
No 52 ( 77.6 )
Yes 15 ( 22.4 )
Plan to use private health insurance
No 59 ( 88.1 )
Yes 8 ( 11.9 )
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Table 5.2: Socio-demographic and clinical characteristics of patients 
with osteoporotic fractures 2013 (n=67) (continued)
Characteristic
n (%)* or mean ± 
standard 
deviation
Receive health insurance from employer
No 65 ( 97.0 )
Yes 2 ( 3.0 )
Fracture-related variables
First fracture
No 8 ( 11.9 )
Yes 59 ( 88.1 )
Duration of fracture (years) 2.7 ± 2.6 )
Fracture type
Vertebral column (spine) 29 ( 43.3 )
Hip 23 ( 34.3 )
Humerus 6 ( 9.0 )
Wrist 2 ( 3.0 )
Other2 7 ( 10.4 )
* Percentages may not add up to 100% due to rounding
1 Includes Medisave, Medifund, Medishield or Eldershield
2 Includes patella, elbow, tibia and pelvis
3-month costs of osteoporotic fractures
Taking the hospital’s perspective, the mean direct medical cost of 
osteoporotic fractures was found to be S$3,886.9 (US$1.0 = S$1.3 as 
of December 2013) [73], of which S$2,884.0 was for inpatient services, 
S$23.4 for A&E services and S$979.6 for outpatient services (Table 
5.3). The main cost driver was inpatient costs (74.2%), while A&E 
services (0.6%) were only a small portion of the total costs. The major 
source of costs for outpatient services was rehabilitation services, 
which accounted for 13.7% of the total cost, or 54.3% of the outpatient 
cost. Findings were similar from the patient’s perspective, with inpatient 
services (57.9%) being the main cost driver of the total cost and 
rehabilitation services (53.9%) being the major cost contributor for 
outpatient services. Overall, the costs from the patient’s perspective 
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were lower than those from the hospital’s due to deductions from 
government subsidies. 
The mean 3-month direct and indirect costs were S$11,438.7 (acute) 
and S$1,015.4 (prevalent), of which 34.7% and 8.0%, respectively, 
accounted for inpatient services. Healthcare expenditure across all 
services was substantially higher in acute patients than prevalent 
patients except for outpatient medications and healthcare and 
community services. Outpatient services were more utilised in the 
prevalent arm, which is evident when comparing the proportion of 
outpatient costs to the total costs. It is noteworthy that a huge disparity 
for outpatient rehabilitation costs was shown in the acute group, and 
the same was true for medications in the prevalent group. Furthermore, 
although the proportion of transport costs and the use of special 
equipment or home/car modifications were similar in both groups, the 
mean costs were much higher in the acute group. Indirect costs were 
also substantially higher in acute patients (Table 5.4). 
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Table 5.3: Direct medical costs incurred by the hospital and patient at different sites 
of care (n=67)
Site of care Hospital1 Patient2
Inpatient
Mean 2,884.0 1,010.2
SD ± 6,650.0 ± 2,405.7
Median 0.0 0.0
90th percentile 13,621.1 4,292.3
Percentage of total cost (%)* 74.2 57.9
Accident & Emergency 
Mean 23.4 13.4
SD ± 89.1 ± 53.4
Median 0.0 0.0
90th percentile 0.0 0.0
Percentage of total cost (%)* 0.6 0.8
Outpatient
Mean 979.6 721.6
SD ± 2,656.1 ± 2,258.3
Median 344.0 226.1
90th percentile 1,477.2 1,018.9
Percentage of total cost (%)* 25.2 41.3
Outpatient physician visits
Mean 263.4 138.5
SD ± 288.0 ± 152.6
Median 208.1 112.4
90th percentile 533.4 332.3
Percentage of total outpatient cost (%)* 26.9 19.2
Outpatient laboratory tests
Mean 19.6 10.1
SD ± 117.1 ± 62.9
Median 0.0 0.0
90th percentile 0.0 0.0
Percentage of total outpatient cost (%)* 2.0 1.4
Outpatient rehabilitations
Mean 532.3 389.2
SD ± 2,615.4 ± 2,211.4
Median 0.0 0.0
90th percentile 56.7 27.3
Percentage of total outpatient cost (%)* 54.3 53.9
Outpatient medications
Mean 164.3 149.7
SD ± 267.4 ± 241.4
Median 65.9 68.0
90th percentile 774.8 700.0
Percentage of total outpatient cost (%)* 16.8 20.7
TOTAL COST
Mean 3,886.9 1,745.2
SD ± 8,463.5 ± 4,043.9
Median 413.1 265.0
90th percentile 14,258.4 4,670.1
* Percentages may not add up to 100% due to rounding
1 Before governement subsidy charges
2 After government subsidy charges
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Table 5.4: Direct and indirect costs incurred by the patient according to patient type 
Acute (n=16) Prevalent (n=51)
Direct medical costs Inpatient
Length of stay (days) 10.1 ± 7.4 0.3 ± 1.4
Mean 3,972.3 80.9
SD ± 3,543.7 ± 428.3
Median 3,684.3 0.0
90th percentile 9,025.7 0.0
Percentage of total cost (%)* 34.7 8.0
Accident & Emergency 
Mean 38.9 5.4
SD ± 81.9 ± 38.5
Median 0.0 0.0
90th percentile 174.0 0.0
Percentage of total cost (%)* 0.3 0.5
Outpatient
Mean 38.9 5.4
SD ± 81.9 ± 38.5
Median 0.0 0.0
90th percentile 174.0 0.0
Percentage of total cost (%)* 0.3 0.5
Outpatient physician visits
Mean 212.1 115.4
SD ± 115.1 ± 156.5
Median 194.5 56.2
90th percentile 387.1 209.2
Percentage of total outpatient cost (%)* 11.0 30.5




SD ± 125.6 ± 17.5
Median 0.0 0.0
90th percentile 150.7 0.0
Percentage of total outpatient cost (%)* 1.6 0.9
Outpatient rehabilitations
Mean 1,541.4 27.8
SD ± 4,421.5 ± 179.9
Median 0.0 0.0
90th percentile 8,257.4 0.0
Percentage of total outpatient cost (%)* 80.2 7.4
Outpatient medications1
Mean 138.0 231.2
SD ± 236.1 ± 414.9
Median 54.7 104.1
90th percentile 503.4 783.4
Percentage of total outpatient cost (%)* 7.2 61.2
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Table 5.4: Direct and indirect costs incurred by the patient according to patient type (continued)
Acute (n=16) Prevalent (n=51)
Direct non-medical costs Transport
Mean 121.9 28.1
SD ± 128.1 ± 29.4
Median 74.9 16.5
90th percentile 367.3 66.4
Percentage of total cost (%)* 1.1 2.8
Other healthcare and community 
services
Mean 157.8 372.4
SD ± 334.1 ± 438.4
Median 0.0 0.0
90th percentile 850.5 975.0
Percentage of total cost (%)* 1.4 36.7
Special equipments and home/car 
modifications
Mean 376.6 19.9
SD ± 685.6 ± 68.3
Median 67.0 0.0
90th percentile 1,929.7 54.9
Percentage of total cost (%)* 3.3 2.0
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Table 5.4: Direct and indirect costs incurred by the patient according to patient type (continued)
Acute (n=16) Prevalent (n=51)
Indirect costs Absenteeism
Hours of productivity loss 76.7 ± 134.3 1.8 ± 4.5
Mean 609.8 24.0
SD ± 1,062.6 ± 91.3
Median 161.0 0.0
90th percentile 3,069.9 62.6
Percentage of total cost (%)* 5.3 2.4
Informal care
Hours of informal care 237.5 ± 313.5 4.7 ± 5.2
Mean 4,238.5 107.0
SD ± 11,919.0 ± 291.8
Median 858.9 50.0
90th percentile 18,109.5 232.2
Percentage of total cost (%)* 37.1 10.5
TOTAL COST    
Mean 11,438.7 1,015.4
SD ± 14,320.1 ± 1,018.4
Median 5,721.4 839.0
90th percentile 37,642.8 1,775.2
* Percentages may not add up to 100% due to rounding
1 Includes prescription and non-prescription medications
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Discussion 
This prevalence-based COI study provides the first realistic estimate of 
the burden of osteoporosis-related fractures occurring both acutely and 
prevalently in patients in Singapore.  The costs reported indicate that 
these fractures had a substantial financial impact on both the hospital 
and patients. 
The direct medical cost per patient estimated in this present study was 
S$3,886.9 (hospital perspective), and this appears to be similar to 
figures reported in other Asian countries. A study in China reported an 
estimate of approximately CNY$15,736.9 [188] per patient, while in 
Taiwan it costs NT$100,000.0 for the management of osteoporotic 
fractures [189]. However, when taking the patient’s perspective, the 
cost per patient estimate was greatly reduced by more than half to 
S$1,745.2. This is due to the highly subsidised rate of up to 50% for 
SOC or polyclinic visits provided by the government of Singapore. In 
addition, Singaporeans were eligible for inpatient subsidies of up to 65% 
or more depending on the patient’s financial status through means-
testing [190, 191]. Notably, direct medical costs reported in the 
American [192, 193] and European continents [194-196] were much 
higher than those estimated in this study. As the comparisons were
based on different study time periods, applying different methodology 
and/or cost items, in addition to different study time frame among 
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different populations across several continents, caution is required 
when interpreting the differences.
Despite the difference in total costs estimated between hospital’s and 
patient’s perspectives, inpatient costs remained the main cost 
contributor, which is consistent with previous osteoporotic-fracture COI 
studies [192, 193, 197-199]. In terms of outpatient costs, rehabilitation 
services contributed to the bulk of the total expenditure, which is 
understandable since rehabilitation admissions were included in this 
category. Like inpatient admissions, although rehabilitation admissions 
were also eligible for government subsidies in the 6 or 8-bedded wards 
[200]; however, the rehabilitation costs were significantly lower than 
inpatient admissions, perhaps because of lower ward charges and 
fewer resources used in addition to a shorter LOS. Often, the high cost 
in inpatient services are strongly correlated to LOS, with a higher LOS 
resulting in higher costs [121, 122]. Though perhaps not intuitive, the 
health consequences of shortened hospital stays may in fact be 
positive, if coupled with adequate rehabilitation services after discharge. 
One study [201] reported significant cost savings when patients had 
early discharge from the hospital succeeded by community-based 
rehabilitation, which allows for faster retraining of physical 
independence and other activities of daily living. This study suggests 
that attempts to expedite early discharge from hospital to a community-
based rehabilitation setting may be worthwhile in reducing overall costs.
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Cost of osteoporosis-related fractures within the first 4 weeks of 
occurrence is concerning, with healthcare use being significantly higher 
when compared to prevalent patients. This vast disparity was mainly 
due to inpatient and outpatient rehabilitation costs that greatly 
increased the burden for acute cases, which is attributed to longer LOS, 
multiple diagnostic tests and higher resource consumption [121, 122, 
202]. Complications and comorbidities were also more likely to occur 
within the first few weeks following a fracture, and these results in 
higher healthcare costs [188, 203, 204].
In contrast, direct non-medical costs were higher in the prevalent group, 
with healthcare and community services being the greatest generator 
of costs. The main reason for the difference is that domestic helpers 
were employed by majority of the prevalent patients whereas 
caregivers such as family members were the main source of 
assistance in the acute group. As expected, transport costs and the 
utilisation of special equipment and home/car modifications were 
noticeably higher in the acute arm. Due to the acute phase of the 
fracture, private or public ambulances were mainly used as the main 
mode of transportation, which were more costly than public transport or 
personal car. Furthermore, all acute patients had no previous fracture, 
hence the need for special aids such wheelchairs or walkers, in 
addition, home modifications such as the installation of ramps and 
handlebars also played a role in the high costs. This finding indicates a 
need to implement equipment rental services within the hospital 
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compound and/or subsidies and programs for home modifications for 
patients, particularly elderly patients with financial difficulties. 
In this study, indirect costs were also examined. When the whole 
patient sample is considered, the estimated cost of absenteeism was 
fairly low because few of the patients were below 65 years of age and 
working. Informal care was the most significant cost contributor when 
the fracture was recent; a majority of caregivers were the patient’s 
spouse who had mostly retired or the patient’s children who had to give 
up their remunerated work. Contrary to the common opinion that 
indirect costs far exceed direct costs [20, 103], the findings in this study 
were less decisive. However, similar findings were reported in two 
osteoporotic fracture-related COI studies where direct costs were 
higher than indirect costs [61, 205]. The proper way of estimating and 
including indirect costs has been subjected to considerable debate [31, 
32]; therefore, the higher costs seen in other studies might be due to 
an overestimation of the true cost or the use of a different methodology 
than those applied in this study. The present study’s cost estimates 
from the hospital’s perspective are noticeably much lower than those 
obtained by three previous studies done in Singapore [181, 206, 207]. 
Chen et al [206] estimated an average cost of S$9,347.5, while 
S$7,367.0 was reported by Wong et al [207] and S$10,515.0 by Lee et 
al [181]. However, it should be noted that these studies had different 
study durations and only estimated hospitalisation costs of hip fractures.
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Osteoporosis is a silent condition and in the absence of a fragility 
fracture, it can go undetected for many years. Usually by the time a 
fracture occurs, the consequences of high healthcare costs are 
unavoidable. Therefore, prevention of fractures using the ‘case-finding’ 
approach should be adopted (i.e. subjects at high risk of fractures 
should be identified and treated) [208].
This study is not without limitations. First, patients were selected from a 
single tertiary hospital, which limits the study’s external validity. 
Second, due to the small sample size, regression analysis to determine 
the predictors of total costs could not be established; therefore, further 
research in this area is warranted to draw a more definitive conclusion. 
Conclusion
This study provides a comprehensive cost analysis for patients with 
osteoporotic fractures in Singapore. The results indicate that fragility 
fractures represent a large cost burden to the healthcare system during 
the first 4 weeks post-fracture. Inpatient hospitalisations were 
associated with the highest cost borne by both the hospital and patient, 
and informal care costs dominated indirect costs. This study’s follow-up 
period of three months may seem short for chronic disease cost
assessment. Future studies with a longer data collection period or 
extrapolation using modelling techniques are needed. 
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With an aging population, the prevalence of osteoporosis-related 
fractures in Singapore will continue to grow in the years to come, 
resulting in a heavy burden on health budgets. Better knowledge of the 
financial consequences of fragility fractures will enable health-system 
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Chapter 6 Conclusion and Future Studies
Major Findings
The first study of this thesis examined the methods used in the 
identified COI studies of DM and found that the studies varied 
considerably in their study design, perspective and included cost 
categories. Direct costs were included in the majority of the studies, 
with hospital inpatient care, physician services and medications serving 
as the most commonly used cost categories. Furthermore, amongst the 
reviewed studies, the societal perspective was the most commonly 
taken. The findings regarding the economic impact of DM reported 
estimated total annual costs that ranged from US$141.6 million to 
US$174.0 billion; direct costs ranged from US$150.0 to US$14,060 
pppy whereas indirect costs ranged from US$39.6 to US$7,164 pppy. 
Inpatient cost was the major contributor to direct cost in half of the 
studies that included inpatient costs, physician services and 
medications. DM-related excess costs between DM patients and non-
DM patients ranged from US$123.1 to US$10,837 pppy with the 
excess cost ratio ranging from 1.5 to 4.4. The cost ratio for a patient 
with DM complications to a patient without them ranged from 1.9 to 2.1.
In the second study conducted for this thesis, the total direct medical 
cost of T2DM was estimated with a mean annual cost of S$2,034.6, of 
which 60.8% was accounted for by inpatient services, 35.1% by 
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outpatient services and 4.1% by A&E services. The major source of 
cost for outpatient services was physician visits, which accounted for 
22.6% of the total healthcare expenditure and 64.0% of total outpatient 
expenditure. Independent determinants of total costs were DM 
interventions such as the use of insulin only and the combination of
oral medications and insulin as well as having cerebrovascular, 
cardiovascular, peripheral vascular disease and nephropathy 
complications. 
The third study estimated the mean annual direct medical cost of 
stroke to be S$12,473.7, of which 93.6% was accounted for by 
inpatient services, 4.9% by outpatient services and 1.5% by A&E 
services. Healthcare expenditure across all services was substantially 
higher in acute patients than prevalent patients. The mean annual 
costs were S$22,721.3 (acute) and S$2,226.2 (prevalent), of which 
95.5% and 73.5%, respectively, accounted for inpatient services. 
Outpatient services were more utilised in the prevalent arm. 
Independent determinants of greater total costs were stroke types, 
such as IS, SAH and ICH, shorter post-stroke period, more than one 
complications and a greater number of comorbidities. 
In the final study, the total direct and indirect costs of osteoporotic 
fractures in Singapore were estimated. The mean annual direct 
medical cost taking the hospital’s perspective was found to be 
S$3,886.0, of which S$2,884.9 was for inpatient services, S$23.4 for 
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A&E services and S$979.6 for outpatient services. Of the total 
healthcare expenditure, the main cost driver was inpatient costs, while 
A&E services were only a small portion of the total costs. The major 
source of costs for outpatient services was rehabilitation services, 
which accounted for 13.7% of the total healthcare expenditure and 54.3% 
of total outpatient expenditure. Findings were similar from the patient’s 
perspective, with inpatient services being the main cost driver of the 
total costs while rehabilitation services were the major cost contributor 
for outpatient services. Overall, the costs from the patient’s perspective 
were much lower due to deductions from government subsidies.
Comparing acute and prevalent patients, the mean annual direct and 
indirect costs were S$11,438.7 (acute) and S$1,015.4 (prevalent). 
Direct costs were higher than indirect costs, with the bulk of costs 
incurred by inpatient services. Healthcare expenditure across all 
services was substantially higher in acute patients than prevalent 
patients, except for outpatient medications and healthcare and 
community services. 
Major Contributions
This thesis has contributed new information on the economic burden of 
DM, stroke and osteoporosis-related fractures in Singapore that was 
previously unavailable. This research not only suggests the need for 
management of these chronic conditions, but also appropriate 
healthcare decision-making. First, to the best of our knowledge, this 
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thesis was the first to describe the methods and summarise the 
findings reported in published DM COI studies from 2007 to 2011. This 
led to the finding of the strengths and limitations of the various methods 
utilised as well as a description of how the application of different 
methods influenced reported cost estimates. Second, this thesis 
provided comprehensive and robust information regarding the financial 
burden of DM, stroke and osteoporotic fractures in Singapore by 
estimating both direct and indirect costs (osteoporotic fractures) from 
the hospital’s and patient’s perspective. Important suggestions were 
proposed to local decision-makers such as the government, healthcare 
professionals, policymakers and patients, with the aim of reducing the 
economic burden by intervention programs or the reallocation of 
resources to those of higher priority. Third, this thesis revealed the 
predictors of total costs in both DM and stroke. As such, there is an 
imperative need for healthcare institutions to review current guidelines 
on effective discharge planning and develop patient-targeted disease 
management programs to reduce overall LOS as well as complications 
and comorbidities. 
Major Limitations
The limitations of the studies in this thesis have been discussed in 
details in the individual chapters and are briefly summarised here. First, 
data for both DM and stroke patients were drawn from a healthcare 
database and, as such, relied on the accuracy and completeness of 
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those records. Second, intangible costs were not examined; hence the 
true cost of the disease has likely been underestimated. Third, the 
study population was limited to the public healthcare sector in 
Singapore. Therefore, the findings may not be generalisable to the 
entire population. 
Future Studies
Based on the findings obtained from the above studies, this thesis 
raises new research questions that should be addressed in the future.
 Economic evaluations alongside controlled intervention studies are 
needed to draw definitive conclusions, especially in stroke and 
osteoporosis patients, in order to determine if the changes in 
severity of the disease, as assessed by lab-derived measurements 
would alter the overall cost.
 The predictors of total cost in patients with osteoporotic-fractures 
could be estimated with a larger sample. 
 Studies could incorporate patients with and without the disease 
(matched-cohort) so that estimated costs can be attributed 
exclusively to the disease.
 Further pharmacoeconomic evaluations such as cost-effectiveness 
and cost-utility analysis alongside outcomes research surveys (i.e. 
health-related quality of life) could be conducted. The results would 
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Appendices
Appendix I Baseline (Acute) Cost of Osteoporotic Fractures Questionnaire
Thank you for your participation in this questionnaire. This study will provide information about the total 
cost of osteoporotic fractures and resource utilisation associated with the fracture, which will be used to 
assist in future healthcare planning. 
This study has been approved by the Institutional Review Board/Ethics Committee.
You are asked to fill in a simple confidential questionnaire assessing the direct costs (such as 
expenditures on prescription and over-the-counter medications, services by healthcare providers etc.) 
and indirect costs (such as the value of work lost) due to your fracture. 
If you have any questions or wish for further information about this study please contact  
____________________.
INTERVIEW DATE:  |     |     | / |     |     | / |     |     |     |     |
                                    MONTH      DAY             YEAR
TIME START: |     |     |:|     |     |   AM                                      TIME END: |     |     |:|     |     | AM
                         PM                                                                                     PM
TOTAL TIME TAKEN FOR INTERVIEW:                                   MINUTES
COST OF OSTEOPOROTIC FRACTURE SURVEY
(BASELINE ≤ 4 WEEKS)
Hospital: SURVEY ID: |     |     |     |     
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SECTION A GENERAL INFORMATION
We would like to obtain your contact number so we can send a text or phone call to remind you 
about the 3-month follow-up. Please be assured that your contact number will remain confidential. 
Thank you. 
Contact number: _____________________
*QA1. When did this fracture occur? 
_____/_____/_____ (day/ month/ year)




2 Rib 3 Hip 4 Wrist
5 Other
If other, please specify _____________
QA3. Is this your first fracture?
1 Yes 2 No
If no, please specify the number of previous fractures _______ and the type(s) of fracture 
________
QA4. Are you a citizen or permanent resident of Singapore?
1 Yes 2 No 3 Don’t know 
*QA5. Marital status: 
1 Married 2 Widow 3 Single 4 Divorced
*QA6. Highest level of education:
1 No school 2 Primary 3 Secondary 4 ITE
5 Pre-U/JC 6 Polytechnic 7 University 
QA7. Gross household monthly income:
1 No income 2 Less than $1,000 3 $1,000 - $2,999 4 $3,000 - $4,999
5 $5,000 - $6,999 6 $7,000 or above
QA8. Do you smoke?
1 Yes 2 No 
*QA9. What is your current employment status?
1
Employed    
(go to QA9.1)
2
Unemployed    
(go to QA9.2)
3
Retired         
(go to QA9.3)
4 Other (go to QA9.4)
QA9.1. 1) What is your occupation? _____________
    2) How many hours do you work per day _______ and days per week ______
  3) Since the occurrence of your fracture, how many days have you taken time off from work due 
to the fracture and/or to attend medical appointments? ____ days
  4) Since the occurrence of your fracture, how many days have you had difficulty working at your 
job due to your fracture? ____ days
    5) Please estimate the percent your work capacity that has been reduced due to the fracture  
___ %
QA9.2. 1) Unemployed because of:
          a) Your fracture b) Other health problems c) Unable to find work
                 d) Other, please specify _____________
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QA9.3. 1) What was your occupation at the time you retired? __________
     2) Did you retire due to your fracture? Yes/No
    3) Do you receive a pension (CPF)? Yes/No
QA9.4. 1) Other, please specify ________________
*QA10. What is your current living arrangement?
1 Live alone 2




Live in nursing 
home 
4 Other
If other, please specify __________








If other, please specify _________
QA12. Did your caregiver miss work, leave their job or change jobs because they had to care for 
you due to your fracture?
1








4 Other (go to QA12.4)
QA12.1. 1) How many days of missed work since the onset of your fracture? ______ days
      2) What is their occupation? ____________
   3) How many hours of care have you received from your caregiver per week on average since 
the onset of your fracture? _________ hours
   4) Is your caregiver paid for the services they provide to you? Yes/No
If yes, how much S$__________
QA12.2. 1) What was their occupation before leaving the job? _____________
      2) How many hours worked per day ________ and days per week ________
QA12.3. 1) What was their previous job? _________
      2) How many hours worked per day ________ and days per week ________ at the previous
job
             3) How many hours worked per day ________ and days per week ________ at the new job
QA12.4. 1) Other, please specify ___________
QA13. Do you currently receive money from Medifund? 
1 Yes 2 No 3 Don’t know
QA14. Do you plan to use Medisave, Medishield, Medifund or Eldershield to claim for the expenses 
related to your fracture?
1 Yes 2 No 3 Don’t know 
If yes, please specify Medisave, Medishield, Medifund or Eldershield ______________
QA15. Do you plan to use any private health insurance—this includes any Medisave-approved 
Integrated Shield plans offered by a private insurer (e.g. NTUC Income’s IncomeShield)—to 
claim for the expenses related to your fracture? 
1 Yes 2 No 3 Don’t know 
If yes, please specify the name of the insurer ______________
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QA16. Do you have any health insurance through your employer? 
1     Yes 2 No 3 Don’t know 
If yes, please specify name of insurer ______________and 
Do you plan to use this insurance to claim for the expenses related to your fracture? (Yes/No)
The following sections ask about the use of health services as a result of your fracture. Some of these 
questions ask for information that may be difficult for you to remember. It would be better if you could 
provide us with a copy of the bills or receipts for any medical care visits you have had since the occurrence 
of your fracture, along with the bottles of your prescription medications. If possible, please make those 
available, as it will greatly reduce the time required to complete this questionnaire.
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SECTION B INPATIENT SERVICES
ACUTE CARE HOSPITAL/COMMUNITY HOSPITAL
Have you been hospitalized due to your fracture? These include both government and private hospitals.
1    Yes 2     No (please go to Section C)
If yes, please specify which hospital ______________
How many times were you admitted overnight due to your fracture?  
Number of admissions:
For each of the inpatient admissions you listed, we are going to ask you some additional questions in the table below.
[If QB1 = Yes, complete QB3-QB9 for each admission] 
QB3. What was the name of the hospital where [fracture patient’s name] was admitted?
QB4. What was the date of admission? 
QB5. What was the date of discharge?
QB6. What type of transportation did [fracture patient’s name] use to travel to the hospital — ambulance, taxi, bus, MRT, personal car, walk, or other (please list)?
[1 = Ambulance, 2 = Taxi, 3 = Bus, 4 = MRT, 5 = Personal Car, 6 = Walk, 7 = Other: please specify]
QB7. Did [fracture patient’s name] pay for this admission using any of the following sources: Medisave, Medishield, Medifund or private insurance? Please list all that 
apply. [1 = Medisave, 2 = Medishield 3 = Medifund, 4 = Private insurance, 5 = Other: please specify] 
QB8. What was the total charge before government subsidy for the hospital admission (in SGD)?
QB9. What was the total charge after government subsidy for the hospital admission (in SGD)?
QB10. Is the total charge based on original receipts? [1 = Yes, 2 = No]
[Repeat for each hospital admission]
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2 = Taxi       
3 = Bus
4 = MRT
5 = Personal 
      Car
6 = Walk
7 = Other: please specify]
QB7.                





4 = Private    
Insurance
5 = DK*
6 = Other: 
please specify]
QB8. 
























*DK = Don’t know
Please 
specify 
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SECTION C EMERGENCY DEPARTMENT SERVICES
QCC1. Have you at any time after your fracture received care in a hospital emergency department that did not result in a hospitalisation (i.e. not 
admitted directly to the hospital)?
1     Yes 2     No (go to Section D)
If yes, please specify the number of times you received care in the emergency department:
For each of the emergency department visits you listed, we are going to ask you some additional questions in the table below.
[If QC1 = Yes, complete QC2-QC12 for each of the listed admissions]
QC2. What was the name of the hospital where [fracture patient’s name] received emergency department care?
QC3. What type of transportation did [fracture patient’s name] use to travel to the emergency department — ambulance, taxi, bus, MRT, personal car, walk, or 
other (please list)? [1 = Ambulance, 2 = Taxi, 3 = Bus, 4 = MRT, 5 = Personal Car, 6 = Walk, 7 = Other: please specify]
QC4. What was the duration of the visit? Please list to the nearest hour. 
QC5. Who accompanied [fracture patient’s name] to the hospital?
QC6. Was the visit due to [fracture patient’s name] fracture? [1 = Yes, 2 = No, 3 = Don’t know]
QC7. [If QC6 = No] Please list the reasons for the visit.
QC8. How much did [fracture patient’s name] pay out of pocket (in SGD) for this visit?
QC9. Did [fracture patient’s name] pay for this visit using any of the following sources: Medisave, Medishield, Medifund or private insurance? Please list all that 
apply. [1 = Medisave, 2 = Medishield, 3 = Medifund, 4 = Private Insurance, 5 = Don’t know, 6 = Other: please specify]
QC10. What was the total charge before government subsidy for the hospital visit (in SGD)?
QC11. What was the total charge after government subsidy for the hospital visit (in SGD)?
QC12. Is the total charge based on original receipts? [1 = Yes, 2 = No]
[Repeat for each emergency department visit]
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2 = Taxi      
3 = Bus
4 = MRT
5 = Personal Car
6 = Walk
7 = Other: please specify]
QC4.




Was the visit 
due to your 
fracture

















*DK = Don’t know
Please 
specify 
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Responses to questions about emergency department visits (cont’d)
QC8.
(S$) value paid out of 
pocket 
QC9.
Other sources of payment 
[1 = Medisave 
2 = Medishield
3 = Medifund
4 = Private Insurance
5 = DK*
6 = Other: please specify]
QC10.
Total bill in (S$) 
before subsidy
QC11. 
Total bill in (S$) 
after subsidy
QC12. 
Is the total charge 




S$100.00 1 $$350.00 S$100.00 1
*DK = Don’t know
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SECTION D OUTPATIENT SERVICES
HOSPITAL OUTPATIENT
QD1. Have you at any time after your fracture received medical care at a hospital outpatient clinic? These may include any visits for treatment, surgery, health 
screenings, check-ups, physiotherapy, occupational therapy, or any other type of care received at a hospital outpatient clinic.
11     Yes 2     No (please go to QD15)
If yes, please specify the number of times you visited a hospital outpatient clinic:
For each of the outpatient hospital visits you listed, we are going to ask you some additional questions in the table below.
[If QD1 = Yes, complete QD2-QD14 for each of the listed visits] 
QD2. What was the name of the hospital where [fracture patient’s name] received care?
QD3. What was the name of the department or specialty where [fracture patient’s name] received care?
QD4. Was this a private facility or a public facility? 
[1 = Private facility, 2 = Public facility, 3 = Don’t know]
QD5. What type of transportation did [fracture patient’s name] use to travel to the clinic — taxi, bus, MRT, personal car, walk, or other (please list)? 
QEB1. [1 = Taxi, 2 = Bus, 3 = MRT, 4 = Personal Car, 5 = Walk, 6 = Other: please specify]
QD6. What was the duration of the visit? Please list to the nearest hour. 
QD7. Who accompanied [fracture patient’s name] to the hospital?
QD8. Was the visit due to [fracture patient’s name] fracture? [1 = Yes, 2 = No, 3 = Don’t know]
QD9. [If QD8 = No] Please list the reasons for visit.
QD10. How much did [fracture patient’s name] pay out of pocket (in SGD) for this visit?
QD11. Did [fracture patient’s name] pay for this admission using any of the following sources: Medisave, Medishield, Medifund or private insurance? Please list all that 
apply. [1 = Medisave, 2 = Medishield, 3 = Medifund, 4 = Private Insurance, 5 = Don’t know, 6 = Other: please specify]
QD12. What was the total charge before government subsidy for the outpatient visit (in SGD)?
QD13. What was the total charge after government subsidy for the outpatient visit (in SGD)?
QD14. Is the total charge based on original receipts? [1 = Yes, 2 = No] [Repeat for each visit]
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[1 = Private facility




[1 = Taxi           
2 = Bus                        
3 = MRT
4 = Personal 
     Car
5 = Walk
6 = Other: please specify]
QD6.





Example National University 
Hospital (NUH)






*DK = Don’t know
Please 
specify 
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Were you visiting 







List reasons why 
you were visiting
QD10.
(S$) Value paid out 
of pocket
QD11.
Other sources of payment
[1 = Medisave 
2 = Medishield
3 = Medifund
4 = Private Insurance
5 = DK*
6 = Other: please specify]
QD12.
Total bill in (S$) 
before subsidy
QD13. 









receipts?              
[1 = Yes, 
2 = No]
Example 1 Muscle 
strengthening 
related to fracture






*DK = Don’t know
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LABORATORY TESTS
QD15. Have you at any time after your fracture undergone laboratory tests at a hospital outpatient clinic? These may include undergoing any tests such as full 
blood count, renal function tests, x-ray, CAT scan, MRI, bone mineral density scan etc. 
1     Yes 2     No (please go to QD29)
If yes, please specify the number of tests you have undergone at a hospital outpatient clinic: 
For each of the tests you listed, we are going to ask you some additional questions in the table below.
[If QD15 = Yes, complete QD16-QD28 for each of the listed visits] 
QD16. What was the name of the hospital where [fracture patient’s name] received care?
QD17. What was the name of the department or specialty where [fracture patient’s name] received care?
QD18. Was this a private facility or a public facility? 
[1 = Private facility, 2 = Public facility, 3 = Don’t know]
QD19. What type of tests did [fracture patient’s name] undergo?
QD20. What type of transportation did [fracture patient’s name] use to travel to the clinic—taxi, bus, MRT, personal car, walk, or other (please list)? 
QEB2. [1 = Taxi, 2 = Bus, 3 = MRT, 4 = Personal Car, 5 = Walk, 6 = Other: please specify]
QD21. What was the duration of the visit? Please list to the nearest hour. 
QD22. Who accompanied [fracture patient’s name] to the hospital?
QD23. Was the visit due to [fracture patient’s name] fracture? [1 = Yes, 2 = No, 3 = Don’t know]
QD24. How much did [fracture patient’s name] pay out of pocket (in SGD) for this visit?
QD25. Did [fracture patient’s name] pay for this admission using any of the following sources: Medisave, Medishield, Medifund or private insurance? Please list all that 
apply. [1 = Medisave, 2 = Medishield, 3 = Medifund, 4 = Private Insurance, 5 = Don’t know, 6 = Other: please specify]
QD26. What was the total charge before government subsidy for the hospital labs (in SGD)?
QD27. What was the total charge after government subsidy for the hospital labs (in SGD)?
QD28. Is the total charge based on original receipts? [1 = Yes, 2 = No] [Repeat for each visit]
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[1 = Private facility






[1 = Taxi                             
2 = Bus
3 = MRT
4 = Personal       
  Car
5 = Walk
6 = Other: please specify]
QD21.
Duration of the 
visit
Example National University 
Hospital (NUH)
Orthopaedic 2 Bone mineral 
density scan






*DK = Don’t know
Please 
specify 
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(S$) Value paid out 
of pocket
QD25.
Other sources of payment
[1 = Medisave 
2 = Medishield
3 = Medifund
4 = Private Insurance
5 = DK*
6 = Other: please specify]
QD26.
Total bill in (S$) 
before subsidy
QD27. 




Is the total 
charge based on 
original receipts?              
[1 = Yes, 
2 = No]






*DK = Don’t know
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PRIMARY CARE CLINICS
QD29. Have you at any time after your fracture received medical care at a primary care clinic? These may include any visits at government polyclinics or private 
general practitioners or any other type of care received at a primary care clinic.
1    Yes 2     No (please go to Section E)
If yes, please specify the number of times you visited a primary care clinic: 
  
For each of the outpatient primary care clinic visits you listed, we are going to ask you some additional questions in the table below.
[If QD29 = Yes, complete QD30-QD41 for each of the listed visits.] 
QD30. What was the name of the clinic where [fracture patient’s name] received care?
QD31. Was this a private facility or a public facility? 
[1 = Private facility, 2 = Public facility, 3 = Don’t know]
QD32. What type of transportation did [fracture patient’s name] use to travel to the clinic — taxi, bus, MRT, personal car, walk, or other (please list)? 
QEB3. [1 = Taxi, 2 = Bus, 3 = MRT, 4 = Personal Car, 5 = Walk, 6 = Other: please specify]
QD33. What was the duration of the visit? Please list to the nearest hour. 
QD34. Who accompanied [fracture patient’s name] to the primary care clinic?
QD35. Was the visit due to [fracture patient’s name] fracture? [1 = Yes, 2 = No, 3 = Don’t know]
QD36. [If QD35 = No] Please list the reasons for visit.
QD37. How much did [fracture patient’s name] pay out of pocket (in SGD) for this visit?
QD38. Did [fracture patient’s name] pay for this visit using any of the following sources: Medifund，private insurance, Chronic Disease Management Programme 
(CDMP) or Primary Care Partnership Scheme (PCPS)? Please list all that apply. [1 = Medifund, 2 = Private Insurance, 3 = Chronic Disease Management 
Programme (CDMP), 4 = Primary Care Partnership Scheme (PCPS), 5 = Other: please specify]
QD39. What was the total charge before government subsidy for the primary care visit (in SGD)?
QD40. What was the total charge after government subsidy for the primary care visit (in SGD)?
QD41. Is the total charge based on original receipts? [1 = Yes, 2 = No] [Repeat for each visit]
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Private or public 




Mode of transportation 
[1 =Taxi
2 = Bus          
3 = MRT        
4 = Personal  
Car
5 = Walk       
6 = Other: please specify]
QD33.





Were you visiting 
















*DK = Don’t know
Please 
specify 
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(S$) Value paid out of 
pocket
QD38.
Other sources of payment 
[1 =Medifund 
2 = Private Insurance 
3 = CDMP (chronic disease management program)
4 = PCPS (primary care partnership scheme)
5 = Other: please specify]
QD39.
Total bill in (S$) 
before subsidy
QD40. 
Total bill in (S$) 
after subsidy
QD41. 
Is the total charge 
based on original 
receipts?   
[1 = Yes, 2 = No]
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SECTION E REHABILITATION
QE1. Have you at any time after your fracture received rehabilitation? These may include any 
rehabilitation at home, day rehabilitation centers and nursing homes.
1 Yes 2 No (please go to Section F)
If yes, please specify the number of times you had rehabilitation sessions: 
We are going to ask you some additional questions about your rehabilitation sessions in the table 
below.
[If QE1 = Yes, complete QE2-QE12 for each rehabilitation service] 
QE2. What was the name of the agency that provided [fracture patient’s name]’s rehabilitation care?
QE3. What was the type of rehabilitation centre? [1 = Home rehabilitation, 2 = Day rehabilitation, 3 = 
Nursing home rehabilitation, 4 = Other: please specify]
QE4. Was this a private or public rehabilitation agency?  [1 = Private rehabilitation agency, 2 = Public, 3 = 
Don’t know]
QE5. What type of transportation did [fracture patient’s name] use to travel to the clinic — taxi, bus, MRT, 
personal car, walk, or other (please list)? 
QEB4. [1 = Taxi, 2 = Bus, 3 = MRT, 4 = Personal Car, 5 = Walk, 6 = Other: please specify]
QE6. On average, how many rehabilitation sessions did [fracture patient’s name] have per month?  
QE7. On average, how long was one rehabilitation session in minutes?  
QE8. On average, how much did [fracture patient’s name] pay out of pocket (in SGD) for one rehabilitation 
session?
QE9. Did [fracture patient’s name] pay for these sessions using any other sources? Please list all that apply. 
[1 = Medisave, 2 = Medishield, 3 = Medifund, 4 = Private Insurance, 5 = Don’t know, 6 = Other: 
please specify]
QE10. What was the total charge before government subsidy for the rehabilitation services (in SGD)?
QE11. What was the total charge after government subsidy for the rehabilitation services (in SGD)?
QE12. Is the total charge based on original receipts? [1 = Yes, 2 = No]
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  Responses to questions about rehabilitation sessions
QE2. Name of agency/nursing home
Example
All Saints Day Rehabilitation 
Centre
QE3. Type of rehabilitation centre
[1 = Home rehabilitation
2 = Day rehabilitation
3 = Nursing home rehabilitation
4 = Other: please specify]
2
QE4. Private or public 
[1 = Private rehabilitation agency
2 = Public rehabilitation agency
3 = DK*]
2
QE5. Mode of transportation  (only applicable to 
day and nursing home rehabilitation)
[1 = Taxi               
2 = Bus
3 = MRT 
4 = Personal Car
5 = Walk
6 = Other: please specify]
1
QE6. Average number of sessions per month
1
QE7. Average duration of each session in minutes
2 hours
QE8. (S$) Value paid out of pocket per session
S$50.00
QE9. Other sources of payment
[1 = Medisave 
2 = Medishield
3 = Medifund
4 = Private Insurance
5 = DK*
6 = Other: please specify]
1
QE10. Total bill in (S$) before subsidy per session
S$350.00
QE11. Total bill in (S$) after subsidy per session
S$100.00
QE12. Is the total charge based on original 
receipts? [1 = Yes, 2 = No]
1
   *DK = Don’t know
Please specify 
costs
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SECTION F MEDICATIONS
PRESCRIPTION MEDICATIONS
Have you taken any prescribed medicine after fracture? These include medications that CANNOT be 
bought over-the-counter and needs a doctor’s prescription.
1 Yes 2 No (go to QF8.)
We are going to ask you some additional questions about each of the medication you have TAKEN
after fracture.
[If QF1 = Yes, complete QF2-QF7 for each medication] 
QF2. What was the name of the prescribed medication? 
QF3. How many days did [fracture patient’s name] take the medication since fracture onset? 
QF4. How many times has [fracture patient’s name] taken the medication per day? 
QF5. What was the medication for? 
QF6. On average, how much did the medication cost per day? 
QF7. Is the total charge based on original receipts? [1 = Yes, 2 = No]
















Cost per day 
(S$)
QF7. 
Is the total charge 
based on original 
receipts?        
[1 = Yes, 2 = No]
Example: 
Vicodin
5 2 Pain relief S$1.00 1
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NON-PRESCRIPTION MEDICATIONS
QF8. Have you taken any non-prescribed medicine/health supplement after fracture? These include 
only medications that CAN be bought over-the-counter and do not need a doctor’s prescription.
1 Yes 2 No (go to Section G)
We are going to ask you some additional questions about each of the medication/health supplement 
you have TAKEN after fracture. These may include calcium tablets, vitamins, fish oil, ginseng, Tiger balm, 
Panadol etc.
[If QF8 = Yes, complete QF9-QF14 for each medication] 
QF9. What was the name of the non-prescribed medication? 
QF10. How many days has [fracture patient’s name] taken the medication since fracture onset? 
QF11. How many times did [fracture patient’s name] take the medication per day? 
QF12. What was the medication for? 
QF13. On average, how much did the medication cost per day? 
QF14. Is the total charge based on original receipts? [1 = Yes, 2 = No]


















Cost per day 
(S$)
QF14. 
Is the total charge 
based on original 
receipts?        
[1 = Yes, 2 = No]
Example: 
Fish oil
2 1 Strengthen 
bones
S$1.00 2
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SECTION G OTHER HEALTHCARE AND COMMUNITY SERVICES
We are now going to ask you about the use of other forms of health services after fracture. 
[For each health service listed in the table below, complete QG1-QG4]
QG1. How many times did [fracture patient’s name] receive this treatment after fracture onset?
QG2. [If QG1 > 0] What medical condition or conditions motivated [fracture patient’s name] to seek this 
treatment?
QG3. [If QG1 > 0] What was the average cost per treatment?
QG4. Is the total charge based on original receipts? [1 = Yes, 2 = No]
[Repeat for each health service]
Responses to questions about use of other health services
Treatment QG1.
Number of times 







Average cost per 
treatment (S$) 
QG4. 
Is the total charge 
based on original 
receipts?         





















8 Other treatment, 
please specify:
                              
________________
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We are now going to ask you about the use of other forms of community services after the fracture. 
[For each community services listed in the table below, complete QG5-QG8]
QG5. How many times did [fracture patient’s name] receive this service after the fracture?
QG6. [If QG5 > 0] What was the reason [fracture patient’s name] requested this service?
QG7. [If QG5 > 0] What was the average cost per service?
QG8. Is the total charge based on original receipts? [1 = Yes, 2 = No]
[Repeat for each health service]
Responses to questions about use of community services
Service QG5.
Number of times 







Average cost per 
treatment (S$) 
QG8. Is the total 
charge based on 
original receipts?         










Community or private 
nursing
6 Community transport
7 Other service, please 
specify:
                              
________________
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SECTION H SPECIAL EQUIPMENT AND HOME/CAR MODIFICATION
We are now going to ask you about the use of special medical equipment or any home/car 
modifications added as a result of the fracture. 
[For each type of medical equipment list in the table below, complete QH1-QH5]
QH1. Did [fracture patient’s name] use this equipment after fracture?
QH2. Was this equipment purchased or rented by [fracture patient’s name], or donated by others?
QH3. What was the cost of purchasing or renting this equipment (SGD)? If rented, please give the rental rate 
in terms of cost per hour, day, week, or month.
QH4. How did [fracture patient’s name] pay for this purchase – out-of-pocket, private insurance or other
(please specify)? [1 = Out-of-pocket, 2 = Private Insurance, 3 = Don’t know, 4 = Other: please 
specify]
QH5. Is the total charge based on original receipts? [1 = Yes, 2 = No]
[Repeat for each type of equipment]





























2 = Private 
Insurance,
3 = DK*,
4 = Other: 
please specify]
QH5. 
Is the total 
charge based on 
original receipts? 















Bed blocks to build 
up bed
9
Rope ladder for 
getting out of bed






















































*DK = Don’t know
You have reached the end of the questionnaire.
Thank you for your participation.
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Appendix II Baseline (Prevalent) Cost of Osteoporotic Fractures Questionnaire
Thank you for your participation in this questionnaire. This study will provide information about the total 
cost of osteoporotic fractures and resource utilisation associated with the fracture, which will be used to 
assist in future healthcare planning. 
This study has been approved by the Institutional Review Board/Ethics Committee.
You are asked to fill in a simple confidential questionnaire assessing the direct costs (such as 
expenditures on prescription and over-the-counter medications, services by healthcare providers etc.) 
and indirect costs (such as the value of work lost) due to your fracture. 
If you have any questions or wish for further information about this study please contact  
____________________.
INTERVIEW DATE:  |     |     | / |     |     | / |     |     |     |     |
                                    MONTH      DAY             YEAR
TIME START: |     |     |:|     |     |   AM                                      TIME END: |     |     |:|     |     | AM
                         PM                                                                                     PM
TOTAL TIME TAKEN FOR INTERVIEW:                                   MINUTES
COST OF OSTEOPOROTIC FRACTURE SURVEY
(BASELINE > 1 YEAR)
Hospital: SURVEY ID: |     |     |     |     
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SECTION A GENERAL INFORMATION
We would like to obtain your contact number so we can send a text or phone call to remind you 
about the 3-month follow-up. Please be assured that your contact number will remain confidential. 
Thank you. 
Contact number: _____________________
*QA1. When did this fracture occur? 
_____/_____/_____ (day/ month/ year)




2 Rib 3 Hip 4 Wrist
5 Other
If other, please specify _____________
QA3. Is this your first fracture?
1 Yes 2 No
If no, please specify the number of previous fractures _______ and the type(s) of fracture 
________
QA4. Are you a citizen or permanent resident of Singapore?
1 Yes 2 No 3 Don’t know 
*QA5. Marital status: 
1 Married 2 Widow 3 Single 4 Divorced
*QA6. Highest level of education:
1 No school 2 Primary 3 Secondary 4 ITE
5 Pre-U/JC 6 Polytechnic 7 University 
QA7. Gross household monthly income:
1 No income 2 Less than $1,000 3 $1,000 - $2,999 4 $3,000 - $4,999
5 $5,000 - $6,999 6 $7,000 or above
QA8. Do you smoke?
1 Yes 2 No 
*QA9. What is your current employment status?
1
Employed    
(go to QA9.1)
2
Unemployed    
(go to QA9.2)
3
Retired         
(go to QA9.3)
4 Other (go to QA9.4)
QA9.1. 1) What is your occupation? _____________
    2) How many hours do you work per day _______ and days per week ______
  3) Since the occurrence of your fracture, how many days have you taken time off from work due 
to the fracture and/or to attend medical appointments? ____ days
  4) Since the occurrence of your fracture, how many days have you had difficulty working at your 
job due to your fracture? ____ days
    5) Please estimate the percent your work capacity that has been reduced due to the fracture  
___ %
QA9.2. 1) Unemployed because of:
          a) Your fracture b) Other health problems c) Unable to find work
                 d) Other, please specify _____________
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QA9.3. 1) What was your occupation at the time you retired? __________
     2) Did you retire due to your fracture? Yes/No
     3) Do you receive a pension (CPF)? Yes/No
QA9.4. 1) Other, please specify ________________
*QA10. What is your current living arrangement?
1 Live alone 2




Live in nursing 
home 
4 Other
If other, please specify __________








If other, please specify _________
QA12. Do you currently receive money from Medifund? 
1 Yes 2 No 3 Don’t know
QA13. Do you plan to use Medisave, Medishield, Medifund or Eldershield to claim for the expenses 
related to your fracture?
1 Yes 2 No 3 Don’t know 
If yes, please specify Medisave, Medishield, Medifund or Eldershield ______________
QA15. Do you plan to use any private health insurance—this includes any Medisave-approved 
Integrated Shield plans offered by a private insurer (e.g. NTUC Income’s IncomeShield)—to 
claim for the expenses related to your fracture? 
1 Yes 2 No 3 Don’t know 
If yes, please specify the name of the insurer ______________
QA16. Do you have any health insurance through your employer? 
1     Yes 2 No 3 Don’t know 
If yes, please specify name of insurer ______________and 
Do you plan to use this insurance to claim for the expenses related to your fracture? (Yes/No)
You have reached the end of the questionnaire.
Thank you for your participation. 
